Exhibit 10.11
SYNTA PHARMACEUTICALS CORP. HAS REQUESTED THAT THE MARKED PORTIONS OF THIS
DOCUMENT BE ACCORDED CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 UNDER THE
SECURITIES ACT OF 1933, AS AMENDED.
[*] DENOTES WHERE CONFIDENTIAL MATERIALS HAVE BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
ASSET PURCHASE AGREEMENT
Asset Purchase Agreement dated as of December 17, 2003, by and among SYNTA
PHARMACEUTICALS CORP., a Delaware corporation ("Buyer"), CANCER GENOMICS, INC.,
a Delaware corporation ("CG"), KAVA PHARMACEUTICALS, INC., a Delaware
corporation ("Kava"), SINGLEPIXEL BIOMEDICAL, INC., a Delaware corporation
("SinglePixel"; CG, Kava and SinglePixel shall singly and collectively be
referred to herein as a "Seller" or "Sellers") and CMAC, LLC, a Delaware limited
liability company ("Stockholder").
This Agreement sets forth the terms and conditions upon which the Buyer
will purchase from the Sellers, and Sellers (each severally and not jointly)
will sell to the Buyer, all the assets of such Sellers (other than the Retained
Assets, as hereinafter defined) and the business and goodwill of the Sellers as
a going concern, subject to those liabilities of the Sellers which are
specifically hereinafter described, for the consideration provided herein.
In all instances, except where otherwise provided, each Seller's rights and
obligations hereunder shall be deemed several and not joint among the Sellers.
In consideration of the foregoing, the mutual representations, warranties
and covenants set forth herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties to
this Agreement hereby agree as follows:
ARTICLE I
DEFINITIONS
1.1 DEFINITIONS. For the purposes of this Agreement, all capitalized words
or expressions used in this Agreement shall have the meanings specified in this
Article I (such meanings to be equally applicable to both the singular and
plural forms of the terms defined):
"AFFILIATE" means when used with respect to any Person, if such Person is a
corporation, any officer or director thereof and any Person which is, directly
or indirectly, the beneficial owner (by itself or as part of any group) of more
than fifty percent (50%) of any class of any Equity Security thereof, and, if
such beneficial owner is a partnership, any general or limited partner thereof,
or if such beneficial owner is a corporation, any Person controlling, controlled
by or under common control with such beneficial owner, or any officer or
director of such beneficial owner or of any corporation occupying any such
control relationship.
"AGREEMENT" means this Asset Purchase Agreement (together with all Exhibits
and Schedules hereto) as in effect from time to time.
"BUSINESS DAY" means any day, excluding Saturday, Sunday and any other day
on which commercial banks in Boston, Massachusetts are authorized or required by
law to close.
1
"CHARTER" means the Certificate of Incorporation, Articles of Incorporation
or Organization or other organizational document of a corporation, as amended
and restated through the date hereof.
"CLAIM" means an action, suit, proceeding, hearing, investigation,
litigation, charge, complaint, claim or demand.
"CODE" means the Internal Revenue Code of 1986, and the regulations,
rulings, and court decisions in respect thereof, all as the same shall be in
effect at the time.
"COMMISSION" means the Securities and Exchange Commission and any other
similar or successor agency of the federal government administering the
Securities Act or the Exchange Act.
"ENVIRONMENTAL ACTION" means any administrative, regulatory or judicial
action, suit, demand, claim, notice of non-compliance or violation,
investigation, request for information, proceeding, consent order or consent
agreement relating in any way to any Environmental Law or any Environmental
Permit.
"ENVIRONMENTAL LAW" means any applicable federal, state or local law,
statute, rule, regulation, or ordinance relating to the environment, human
health or safety from pollution or other environmental degradation or Hazardous
Materials.
"EQUITY SECURITY" shall have the meaning given to such term in Section
3(a)(ii) of the Exchange Act.
"ERISA" means the Employee Retirement Income Security Act of 1974, and any
similar or successor federal statute, and the rules, regulations and
interpretations thereunder, all as the same shall be in effect at the time.
"EXCHANGE ACT" means the Securities Exchange Act of 1934, and the rules and
regulations and interpretations of the Commission thereunder, all as the same
shall be in effect at the time.
"GAAP" means generally accepted accounting principles, consistently
applied.
"LIEN" means, with respect to any asset, any mortgage, deed of trust,
pledge, hypothecation, assignment, security interest, lien, charge, restriction,
adverse claim by a third party, title defect or encumbrance of any kind.
"MATERIAL ADVERSE EFFECT" means a material adverse impact or effect on the
assets of a Seller or of the Buyer, as the case may be.
"OFFICER'S CERTIFICATE" means a certificate signed in the name of a
corporation by its President, Chief Executive Officer, Treasurer, Chief
Financial Officer, or, if so specified, the Secretary, acting in his or her
official capacity.
2
"PERSON" means any individual, firm, partnership, association, trust,
corporation, limited liability company, governmental body or other entity.
"PURCHASE DOCUMENTS" means this Agreement, the Non-Competition Agreements,
the Bills of Sale, the Instruments of Assumption, the Patent Assignments, the
Kava Pharmaceutical License Agreement and any other certificate, document,
instrument, stock power, or agreement executed in connection therewith.
"SECURITIES ACT" means the Securities Act of 1933 and the rules,
regulations and interpretations of the Commission thereunder, all as the same
shall be in effect at the time.
"SUBSIDIARY" means, with respect to any Person, any corporation,
association or other entity of which such Person owns at least a majority in
interest of the outstanding capital stock or other Equity Securities having by
the terms thereof voting power under ordinary circumstances to elect a majority
of the directors, managers or trustees thereof.
"TAX" means any federal, state, local or foreign tax of any kind
whatsoever, including any interest, penalty, or addition thereto, whether
disputed or not.
"TAX RETURN" means any return, declaration, report, claim for refund, or
information return or statement relating to Taxes, including any schedule or
attachment thereto, and including any amendment thereof.
"TO STOCKHOLDER'S KNOWLEDGE", "KNOWN TO STOCKHOLDER", "TO THE KNOWLEDGE OF
THE STOCKHOLDER" and words of similar import means the actual knowledge of any
of Xxxxxxx X.X. Xxxxx, Xxxx X. XxXxxxxx, Xxxxxxxx X. Noon and Xxxx X. Xxxxxxxxx
as of the date hereof.
"VALID CLAIM" shall mean a claim in an issued, unexpired patent or in a
pending patent application within the Kava Patents, Single Pixel Patents or CG
Patents that (a) has not been finally cancelled, withdrawn, abandoned or
rejected by any administrative agency or other body of competent jurisdiction,
(b) has not been revoked, held invalid, or declared unpatentable or
unenforceable in a decision of a court or other body of competent jurisdiction
that is unappealable or uappealed within the time allowed for appeal, (c) has
not been rendered unenforceable through disclaimer or otherwise, (d) is not lost
through an interference proceeding or (e) to the extent pending, has not been
pending for longer than five (5) years from the filing date of the earliest
patent application from which the pending application claims priority, provided
that subsequent to such five (5) year period, if the pending claim is issued as
a claim of an issued and unexpired patent within the Kava Patents, Single Pixel
Patents or CG Patents, such claim shall be considered thereafter as a Valid
Claim hereunder.
3
The following terms are defined in the following Sections of this
Agreement:
Term Section
---- -------
Agreement Recitals
Assumed Liabilities 2.1
Bills of Sale 2.8
Business 2.1
Buyer Recitals
Closing 2.7
Closing Date 2.7
Seller Financial Statements 3.4
Gross Revenues 2.5(b)
Indemnifying Party 8.5
Instruments of Assumption 2.9
Losses 8.2
Necessary Permits 3.13
Non-Competition Agreements 6.1
Patent Assignment 6.1
Plan 3.15(a)
Purchased Assets 2.1
Purchase Price 2.2
Retained Assets 2.2
Retained Liabilities 2.4
Stockholder Recitals
ARTICLE II
PURCHASE AND SALE OF ASSETS
2.1 PURCHASE OF ASSETS. Upon the terms and subject to the conditions
contained in this Agreement, at the Closing (as defined in Section 2.7 below),
each Seller shall sell, assign, transfer and convey to Buyer, and Buyer shall
purchase, acquire and accept from each Seller, the business of the respective
Sellers as a going concern (the "Business"), including all of the Sellers'
assets of every kind and description as set forth on SCHEDULE 2.1 hereto (the
"Purchased Assets") (other than those assets included in the Retained Assets as
defined in Section 2.2 below), and subject only to the liabilities and
obligations of the Sellers which are defined in Section 2.3 (the "Assumed
Liabilities"). The Purchased Assets include, without limitation, all assets,
rights, interests and properties of the Sellers (other than those assets
included in the Retained Assets as defined in Section 2.2).
2.2 RETAINED ASSETS. The Sellers will each retain ownership only of such
Seller's cash and cash equivalents on hand and in banks, minute and stock record
books, journals, ledgers and books of original entry and such Seller's rights
under the Purchase Documents (collectively, the "Retained Assets").
4
2.3 ASSUMED LIABILITIES. The Buyer shall assume and agree to pay, perform
and discharge the Assumed Liabilities, and will pay, perform and discharge the
Assumed Liabilities as they become due. The Assumed Liabilities shall consist of
the liabilities of the Sellers listed on SCHEDULE 2.3 attached hereto.
2.4 RETAINED LIABILITIES. The liabilities and obligations which shall be
retained by each of the Sellers (the "Retained Liabilities") shall consist of
all liabilities of such Seller other than Assumed Liabilities, including,
without limitation, the following:
(a) all liabilities of each Seller relating to indebtedness for
borrowed money whether or not such liabilities are reflected on the Seller
Financial Statements;
(b) all liabilities of each Seller or the Stockholder resulting from,
constituting or relating to a breach of any of the representations, warranties,
covenants or agreements of the such Seller or the Stockholder under this
Agreement;
(c) all liabilities of each Seller for Taxes, including any gain and
income from the sale of the Assets and other transactions contemplated herein;
(d) all liabilities for all environmental, ecological, health,
safety, products liability (except as specifically referred to herein) or other
claims pertaining to the Business or the Purchased Assets which relate to time
periods or events occurring on or prior to the Closing Date;
(e) all liabilities of each Seller arising in connection with its
operations unrelated to the Business and all liabilities (including any
liability pursuant to any claim, litigation or proceeding) in connection with
the operation of the Business prior to the Closing except as otherwise
specifically provided herein and any liability of such Seller based on its
tortuous or illegal conduct;
(f) any liability or obligation incurred by each Seller in connection
with the negotiation, execution or performance of this Agreement, including,
without limitation, all legal, accounting, brokers', finders' and other
professional fees and expenses;
(g) all liabilities incurred by each Seller after the Closing Date;
(h) all liabilities or obligations associated with a Seller's
employees, including but not limited to any liability or obligation under or
with respect to any collective bargaining agreement, employment agreement,
unemployment or workers' compensation laws, or any liability or obligation
arising from the decision of Buyer not to offer employment to any such
employees; and
(i) all liabilities and obligations arising out of, resulting from,
or relating to any employee benefit plan, program, or arrangement maintained or
contributed to by each Seller,
5
or any entity which is or has been aggregated with such Seller for purposes of
section 414 of the Code or section 4001 of ERISA.
2.5 PURCHASE PRICE. Upon the terms and subject to the conditions contained
in this Agreement, and in consideration of the sale, assignment, transfer and
delivery of the Purchased Assets and covenants not to compete received from the
Sellers and the Stockholder, Buyer will issue to the Sellers an aggregate of
553,344 shares of the Buyer's common stock, par value $0.0001 per share ("Common
Stock" and the "Consideration Shares", and together with the adjustments set
forth below, the "Purchase Price"). The Consideration Shares shall be
apportioned among the Sellers as follows: 25% to CG, 50% to Kava and 25% to
SinglePixel. Delivery of stock certificates representing the Consideration
Shares shall be made to each of the Sellers at the Closing. The parties agree
that the Purchase Price represents fair consideration and reasonably equivalent
value for the Purchased Assets.
(a) ADJUSTMENTS FOR MILESTONES. Buyer shall make a one-time only
payment:
(i) to Kava, or any of its assignees, of [*] payable in either
cash or shares of the Buyer's Common Stock (at the discretion of the Buyer
and, if such payment is in Common Stock, valued at the then current fair
market value of the Common Stock) in a single payment by wire transfer or
delivery of shares of Common Stock to an account designated in writing by
Kava, or any of its assignees, to Buyer within sixty (60) days of the
commencement by Buyer of a Phase III (or other pivotal) clinical trial for
any drug candidate, the manufacture, use or sale of which infringes one or
more Valid Claims of the Kava Patents (a "Kava Drug Candidate"). For
purposes of this Agreement, "Kava Patents" shall mean any and all patent
filings assigned to Kava or to which Kava has or will have any right,
title or interest, including the issued patents and pending patent
applications under the Kava IP (as defined in SCHEDULE 2.1), and all
non-provisionals, divisionals, continuations, continuations-in-part and
all patents issuing on any of the foregoing, and all foreign counterparts
thereof; together with all registrations, reissues, re-examinations,
supplemental protection certificates and extensions thereof and all
foreign counterparts thereof. In the event that Buyer commences a Phase
III (or other pivotal) clinical trial for a drug candidate, the
manufacture, use of sale of which does not infringe one or more Valid
Claims of the Kava Patents at the time of the commencement of such
clinical trial but the manufacture, use or sale of which later infringes
one or more Valid Claims of the Kava Patents, then Buyer shall make such
one-time only payment under this subsection (i) of Section 2.5(a) within
sixty (60) days of the drug candidate becoming a Kava Drug Candidate under
this Agreement; and
(ii) to SinglePixel, or any of its assignees, [*] payable in
either cash or shares of the Buyer's Common Stock (at the discretion of
the Buyer and, if such payment is in Common Stock, valued at the then
current fair market value of the Common Stock) in a single payment by wire
transfer or delivery of shares of Common Stock to an account designated in
writing by SinglePixel, or any of its assignees, to Buyer within sixty
(60) days of the receipt by Buyer of approval by the Federal Drug
Administration of any SinglePixel diagnostic product, the
6
manufacture, use or sale of which infringes one or more Valid Claims of the
SinglePixel Patents (a "SinglePixel Product"). For purposes of this
Agreement, "SinglePixel Patents" shall mean any and all patent filings
assigned to SinglePixel or to which SinglePixel has or will have any right,
title or interest, including the issued patents and pending patent
applications identified under the SinglePixel IP (as defined in SCHEDULE
2.1), and all non-provisionals, divisionals, continuations,
continuations-in-part and all patents issuing on any of the foregoing, and
all foreign counterparts thereof; together with all registrations,
reissues, re-examinations, supplemental protection certificates and
extensions thereof. In the event that Buyer receives approval by the
Federal Drug Administration of any SinglePixel diagnostic product, the
manufacture, use or sale of which does not infringes one or more Valid
Claims of the SinglePixel Patents at the time of receipt of such approval
but the manufacture, use or sale of which later infringes one or more Valid
Claims of the SinglePixel Patents, then Buyer shall make such one-time only
payment under this subsection (ii) of Section 2.5(a) within sixty (60) days
of the SinglePixel diagnostic product becoming a SinglePixel Product under
this Agreement. For purposes of this Section 2.5, the term "diagnostic
product" means any product which is intended to predict, detect or identify
a disease, determine the presence of a pathologic condition or monitor the
course of disease or therapy in humans or other animals.
(b) ROYALTIES FOR CERTAIN PATENTS. In the event that Buyer
obtains revenue or other measurable economic benefit ("Gross Revenues") from
products or services covered by a Valid Claim in any Kava Patent or CG Patent
(the "Kava Products", and the "CG Products", respectively), Buyer shall pay
to Kava or CG, or any of their assignees, as the case may be, a percentage of
the Gross Revenues received by Buyer or such licensee from sales of such Kava
Product or CG Product as follows: (i) [*]% of Gross Revenues of the Kava
Product, and (ii) [*]% of Gross Revenues of the CG Product. The amount of
such Gross Revenues shall be proportionately adjusted to reflect the
exclusion of the contribution of ingredients or components not directly
related to the Kava Product and/or CG Product, but in no case less than [*]%
of the rates specified above. Any payments by Buyer pursuant to this
subsection shall be made by cash or check within ninety (90) days of the end
of each fiscal year of Buyer in which any applicable sale is made. The
obligations under this section shall continue on a country-by-country basis
until the later of (1) the expiration date, as such date may be modified or
extended, of the last-to-expire patent of the relevant Kava IP or CG IP (as
the case may be) in such country, or (2) ten (10) years from first commercial
sale of the Kava Product or CG Product. For purposes of this Section 2.5, "CG
Patents" shall mean any and all patent filings assigned to CG or to which CG
has or will have any right, title or interest, including the issued patents
and pending patent applications identified under the CG IP (as defined in
SCHEDULE 2.1), and all non-provisionals, divisionals, continuations,
continuations-in-part; and all patents issuing on any of the foregoing, and
all foreign counterparts thereof; together with all registrations, reissues,
re-examinations, supplemental protection certificates and extensions thereof.
(c) THIRD PARTY ROYALTY OFFSET. In the event that in any royalty
period, Buyer, in order to sell any Kava Product or CG Product in any country,
makes royalty payments to one or more third parties ("Third Party Payments") as
consideration for a license to an issued patent or patents owned by such third
party(ies), in the absence of which the Kava Product or CG Product could not
legally be made, used or sold in such country, then Buyer shall have the right
7
to reduce the royalties otherwise due pursuant to Section 2.5(b) above for
such Kava Product or CG Product by [*]% of such Third Party Payments.
Notwithstanding the foregoing, such reductions under this subsection (c)
shall in no event reduce such royalty for such Kava Product or CG Product in
any such country to less than [*]% of the rates otherwise specified above.
2.6 ALLOCATION OF PURCHASE PRICE. The Purchase Price shall be allocated
among the Purchased Assets and the covenants not to compete received from the
Sellers and the Stockholder as set forth in SCHEDULE 2.6 attached hereto. The
Sellers and Buyer shall be bound by such allocation for all purposes and to
account for and report the purchase and sale contemplated hereby for all
financial, accounting and Tax purposes in accordance with such allocation.
2.7 TIME AND PLACE OF CLOSING. The closing of the transactions described
in Sections 2.1 through 2.6 above (the "Closing") shall take place at the
offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., at 11:00 a.m. on
January 9, 2004, or at such other place or time as the parties hereto may agree.
The date and time at which the Closing actually occurs is hereinafter referred
to as the "Closing Date."
2.8 EXECUTION AND DELIVERY OF DOCUMENTS OF TITLE BY THE SELLERS. At the
Closing, each Seller shall execute and deliver to Buyer the form of Xxxx of Sale
attached hereto as EXHIBIT A and such deeds, conveyances, bills of sale,
certificates of title, assignments, assurances and other instruments and
documents as Buyer may reasonably request in order to effect the sale,
conveyance, and transfer of the Purchased Assets from the Sellers to the Buyer.
Such instruments and documents shall be sufficient to convey to Buyer good and
merchantable title in all of the Purchased Assets. Each Seller will, from time
to time after the Closing Date, take such additional actions and execute and
deliver such further documents as Buyer may reasonably request in order more
effectively to sell, transfer and convey the Purchased Assets to Buyer and to
place Buyer in position to operate and control all of the Purchased Assets.
2.9 EXECUTION AND DELIVERY OF DOCUMENTS BY BUYER. At the Closing, Buyer
shall execute and deliver to each Seller an Instrument of Assumption in the form
attached hereto as EXHIBIT B, and such other documents as the Sellers may
reasonably request in order to evidence Buyer's assumption of the Assumed
Liabilities. Buyer will, from time to time after the Closing Date, take such
additional action and deliver such further documents as the Sellers may
reasonably request in order effectively to assume the Assumed Liabilities.
2.10 CONSENT TO ASSIGNMENT. Upon the terms, and subject to the conditions
set forth in this Agreement, each Seller hereby assigns to the Buyer all of the
Purchased Assets which are capable of assignment without the consent of other
parties.
Insofar as any Purchased Asset is not assignable to the Buyer without the
agreement of or novation by or consent to the assignment from another party and
no such agreement, novation or consent has been obtained by such Seller on or
prior to Closing Date, this Agreement shall not constitute an assignment or
attempted assignment if such assignment or attempted assignment would constitute
a breach of Seller's obligations related to such Purchased Asset. In the event
that consent or novation is required to such assignment:
8
(a) the Seller shall use all reasonable endeavors to cooperate with
the Buyer in its efforts to procure such novation or assignment as aforesaid.
The reasonable costs of any such novation or assignment shall be paid by the
Buyer;
(b) unless and until any such Purchased Asset shall be novated or
assigned as aforesaid the Seller shall hold such Purchased Asset and any moneys,
goods or other benefits received thereunder as agent of the Buyer and the Buyer
shall (if such sub-contracting is permissible and lawful under such Purchased
Asset in question) as the Seller's sub-contractor perform all the obligations of
the Seller under such Purchased Asset;
(c) unless and until any such Purchased Asset shall be novated or
assigned, the Seller will (so far as it lawfully may) give such assistance to
the Buyer (and at the Buyer's cost) as the Buyer may reasonably require to
enable the Buyer to enforce its rights under such Purchased Asset and (without
limitation) will provide access to all relevant books, documents and other
information in relation to such Purchased Asset as the Buyer may reasonably
require from time to time.
ARTICLE III
REPRESENTATIONS AND WARRANTIES
OF THE SELLERS AND THE STOCKHOLDER
Each Seller and the Stockholder each hereby represents and warrants to
Buyer as follows:
3.1 ORGANIZATION AND QUALIFICATION. Each Seller is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Delaware. The Stockholder is a limited liability company duly organized, validly
existing and in good standing under the laws of the State of Delaware. The
Stockholder and each Seller have full power and authority to own, use and lease
their properties and to conduct their business as currently conducted and as
proposed to be conducted. The copies of the Stockholder's operating agreement,
as amended to date and certified by an officer of the Stockholder and delivered
to Buyer's counsel prior to the Closing, is true, complete and correct. The
copies of each Seller's Charter and By-Laws, as amended to date, in each case
certified by their respective Secretaries and delivered to Buyer's counsel prior
to the Closing, are true, complete and correct.
3.2 AUTHORITY; NO VIOLATION. Each Seller and the Stockholder has all
requisite corporate power and authority to enter into this Agreement and to
carry out the transactions contemplated hereby. The execution, delivery and
performance of this Agreement by each Seller and the Stockholder have been duly
and validly authorized and approved by all necessary corporate action. This
Agreement constitutes the legal and binding obligation of each Seller and the
Stockholder, enforceable against each of them in accordance with its terms. The
entering into of this Agreement by the Stockholder and each Seller does not, and
the consummation by such Seller and the Stockholder of the transactions
contemplated hereby, including specifically the transfer of the Purchased Assets
to Buyer by such Seller, will not violate the provisions of (a) to the knowledge
of the Stockholder, any applicable federal, state, local or foreign laws, (b)
such
9
Seller's or Stockholder's respective Charter, By-Laws or operating agreement, as
the case may be, or (c) any provision of, or result in a default or acceleration
of any obligation under, or result in any change in the rights or obligations of
such Seller or the Stockholder under, any Lien, contract, agreement, license,
lease, instrument, indenture, order, arbitration award, judgment, or decree to
which such Seller or the Stockholder is a party or by which any of them is
bound, or to which any property of such Seller or the Stockholder is subject.
3.3 SUBSIDIARIES. Each Seller represents and warrants that it has no
Subsidiaries.
3.4 SELLER FINANCIAL STATEMENTS. Attached hereto as SCHEDULE 3.4 are
unaudited consolidating balance sheets as of June 30, 2003 (collectively, the
"Seller Financial Statements") for each Seller. The Seller Financial Statements
have been prepared in accordance with GAAP applied on a consistent basis
throughout the periods covered thereby. The Stockholder represents and warrants
that the Seller Financial Statements fairly present the financial condition and
the results of operation of each Seller and that there are no assets of the
Sellers that are not included in the Seller Financial Statements, except for
assets of any Seller that are not required by GAAP to be included in the Seller
Financial Statements.
3.5 ABSENCE OF CERTAIN CHANGES. Except as otherwise disclosed in SCHEDULE
3.5 attached hereto, since June 30, 2003, there has not been:
(a) any material change in the business, operations, assets,
liabilities, prospects or condition (financial or otherwise) of any Seller;
(b) any obligation or liability incurred by a Seller other than
obligations and liabilities incurred in the ordinary course of business for an
amount not more than $5,000 in each case or $15,000 in the aggregate;
(c) any Lien placed on any of the Sellers' properties or assets which
remains in existence on the date hereof or any payment or discharge of a
material Lien or liability of the Sellers not disclosed on the Seller Financial
Statements or incurred in the ordinary course of business;
(d) any purchase, sale, lease, assignment, transfer or other
disposition, or any agreement or other arrangement for the purchase, sale,
lease, assignment, transfer or other disposition, of any part of the Sellers'
properties or assets, other than purchases for and sales from inventory in the
ordinary course of business, except for fixed assets purchased or other capital
expenditures made in amounts not exceeding $5,000 for any single item and
$25,000 in the aggregate for all such items;
(e) any damage, destruction or loss, whether or not covered by
insurance, adversely affecting a Seller's properties, assets or business;
(f) any declaration, setting aside or payment of any dividend on, or
the making of any other distribution in respect of, any Equity Security of a
Seller, or any direct or
10
indirect redemption, purchase or other acquisition by a Seller of any of its own
Equity Securities, or any issuance by a Seller of any Equity Security;
(g) any labor trouble or claim of unfair labor practices involving a
Seller; any change in the employment contracts of or compensation payable or to
become payable by a Seller to any of its current or former officers, directors,
employees, consultants, or agents, or any bonus payment, loan or arrangement
made to or with respect to any of such officers, directors, employees,
consultants, or agents; or any change in coverage vesting, or benefits available
under any Plan;
(h) any change with respect to a Seller's management or supervisory
personnel;
(i) any contracts, licenses, leases or agreements entered into by a
Seller which are outside the ordinary course of business or which obligate such
Seller for more than $5,000 in any one case or more than $25,000 in the
aggregate or any cancellation, termination, modification, or acceleration by any
party to any contract, license, lease or agreement involving more than $10,000
to which any such Seller is a party or by which any of them is bound;
(j) any amendment or other change (or any authorization to make such
an amendment or change) to such Seller's Charter or By-Laws, except as required
in connection with the consummation of the transactions contemplated hereby;
(k) any postponement or delay in payment of any accounts payable or
other liability of such Seller except in the ordinary course of business
consistent with prior practices;
(l) any cancellation, waiver, compromise or release of any right or
claim either involving more than $10,000 or outside the ordinary course of
business consistent with prior practices;
(m) any other occurrence, action, failure to act or transaction
involving a Seller other than transactions in the ordinary course of business
consistent with prior practices.
3.6 TITLE, SUFFICIENCY AND CONDITION OF ASSETS. Except as disclosed in
SCHEDULE 3.6 hereto, each Seller has good and marketable title to, or a valid
leasehold interest in, all of the Purchased Assets, free and clear of all Liens,
and free of any material infractions or non-compliance with applicable laws and
regulations (collectively, "Defects") and the sale and delivery of the Purchased
Assets to Buyer pursuant hereto shall vest in Buyer good and marketable title
thereto, free and clear of any and all Liens or Defects, other than as disclosed
in SCHEDULE 3.6 hereto or as may be created by Buyer. The Stockholder and each
Seller shall each, prior to the Closing, use their best efforts to cure at their
expense any Defect identified by Buyer. Each Seller owns or leases all property
and assets necessary for the conduct of their respective businesses as such
businesses are presently conducted and are proposed to be conducted, and all
such property and assets are included in the Purchased Assets. To the knowledge
of the Stockholder and except as disclosed in SCHEDULE 3.6 hereto, all tangible
properties and assets owned or leased by such Seller and contained in the
Purchased Assets are in good operating
11
condition and repair, ordinary wear and tear excepted, have been well
maintained, and conform with all applicable laws, statutes, ordinances, rules
and regulations.
3.7 INTELLECTUAL PROPERTY. All patents, patent applications, proprietary
designs, copyrights, trade names, servicemarks, trademarks and trademark
applications and proprietary know how which are currently owned by or licensed
to each Seller are listed in SCHEDULE 3.7 attached hereto ("Intellectual
Property"). Except as set forth in SCHEDULE 3.7, the Intellectual Property is
all of the intellectual property necessary for the operation of the Business as
it is currently conducted. All of each Seller's patents, patent applications and
trademarks have been registered in, filed in or issued by the United States
Patent Office or the corresponding offices of other countries identified in
SCHEDULE 3.7, and have been properly maintained and renewed in accordance with
all applicable laws and regulations in the United States and each such country.
To the knowledge of the Stockholder, all of the issued patents within the
Intellectual Property are currently in compliance with applicable formal legal
requirements (including payment of filing, examination or maintenance fees) and
are valid and enforceable. Except as set forth in SCHEDULE 3.7 and to the
knowledge of the Stockholder, the Intellectual Property's use does not require
the consent of or payment to any other Person. To the knowledge of the
Stockholder and except as set forth in SCHEDULE 3.7, the Intellectual Property
is freely transferable and owned exclusively by each Seller, free and clear of
any Liens. To the knowledge of the Stockholder and except as set forth in
SCHEDULE 3.7, (a) no other Person has an interest in or right or license to use,
or the right to license any other Person to use, any of the Intellectual
Property, (b) there are no claims or demands of any other Person pertaining
thereto and no proceedings have been instituted, or are pending or, to the
knowledge of the Stockholder, threatened, which challenge any Seller's rights in
respect thereof, (c) none of the Intellectual Property is being infringed by
another Person or is subject to any outstanding order, decree, ruling, charge,
injunction, judgment or stipulation, and (d) no Claim has been made or, to the
knowledge of the Stockholder, is threatened charging such Seller with
infringement of any adversely held Intellectual Property. With respect to all
know-how that is included as part of the Intellectual Property, to the knowledge
of the Stockholder, each Seller has taken all reasonable precautions to protect
the secrecy, confidentiality and value of such know-how (including the
enforcement by each Seller of a policy requiring each employee or contractor to
execute proprietary information and confidentiality agreements substantially in
the form of such Seller's standard form, a copy of which has been provided to
Buyer).
3.8 CONTRACTS. Except for contracts, commitments, leases, licenses, plans
and agreements described in SCHEDULE 3.8 attached hereto, no Seller is a party
to or subject to:
(a) any plan or contract regarding or providing for bonuses,
pensions, options, stock purchases, deferred compensation, severance benefits
retirement payments, profit sharing, stock appreciation, collective bargaining
or the like, or any contract or agreement with any labor union;
(b) any employment or consulting contract or contract for personal
services not terminable at will by such Seller without penalty to the Seller;
12
(c) any contract or agreement for the purchase of any commodity,
product, material, supplies, equipment or other personal property, or for the
receipt of any service, other than purchase orders entered into in the ordinary
course of business for less than $5,000 each and which in the aggregate do not
exceed $25,000;
(d) any contract or agreement for the purchase or lease of any fixed
asset, whether or not such purchase or lease is in the ordinary course of
business, for a price in excess of $5,000;
(e) any contract or agreement for the sale of any commodity, product,
material, equipment, or other personal property, or the furnishing by such
Seller of any service, other than contracts with customers entered into in the
ordinary course of business;
(f) any contract or agreement providing for the purchase of all or
substantially all of its requirements of a particular product from a supplier,
or for periodic minimum purchases of a particular product from a supplier;
(g) any contract or agreement concerning a partnership or joint
venture with one or more Persons;
(h) any confidentiality agreement or any non-competition agreement or
other contract or agreement containing covenants limiting such Seller's freedom
to compete in any line of business or in any location or with any Person;
(i) any license agreement (as licensor or licensee);
(j) any contract or agreement with the Stockholder or any present or
former officer, director, consultant, agent or stockholder of such Seller or
with any Affiliate of any of them;
(k) any loan agreement, indenture, note, bond, debenture or any other
document or agreement evidencing a capitalized lease obligation or Indebtedness
to any Person;
(l) any agreement of guaranty, indemnification, or other similar
commitment with respect to the obligations or liabilities of any other Person
(other than lawful indemnification provisions contained in the Charters and
By-Laws of such Seller); or
(m) any other agreement or contract (or group or related agreements
or contracts) under which the consequences of a default or termination could
have a Material Adverse Effect or the performance of which involves
consideration paid or received by the Seller in excess of $5,000.
Copies of all such contracts, commitments, plans, leases, licenses and
agreements have been provided to Buyer prior to the execution of this Agreement,
and all such copies are true, correct and complete and have been subject to no
amendment, extension or other modification as of the date hereof, except such as
are described in SCHEDULE 3.8. Except as listed and described
13
in SCHEDULE 3.8, none of the Sellers, or to the knowledge of the Stockholder,
any other Person, is in default under any such contract, commitment, plan,
lease, license or agreement and each such contact, commitment, plan, lease,
license or agreement is in full force and effect and is valid and enforceable in
accordance with its terms.
3.9 COMPLIANCE WITH LAWS. Each Seller has conducted and is conducting its
business in compliance with applicable federal, state, local or foreign laws,
statutes, ordinances, regulations, rules or orders or other requirements of any
governmental, regulatory or administrative agency or authority or court or other
tribunal relating to it. None of the Sellers are now charged with, and to the
knowledge of the Stockholder, is not now under investigation with respect to,
any possible violation of any applicable law, statute, ordinance, regulation,
rule, order or requirement relating to any of the foregoing. Each Seller has all
licenses, permits, franchises, orders, approvals, accreditations, written
waivers and other authorizations as are necessary in order to enable it to own
and conduct its business as currently conducted and as proposed to be conducted
and to occupy and use its real and personal properties without incurring any
material liability ("Necessary Permits"), except for such licenses, permits,
franchises, orders, approvals, accreditations, written waivers and other
authorizations as would not reasonably be expected to have a Material Adverse
Effect. Except as set forth in SCHEDULE 3.9, no registration, filing,
application, notice, transfer, consent, approval, order, qualification, waiver
or other action of any kind is required by virtue of the execution and delivery
of this Agreement or the consummation of the transactions contemplated hereby to
effect the transfer to Buyer of such Necessary Permits. To the knowledge of the
Stockholder, each Seller is in full compliance with the terms and conditions of
all Necessary Permits.
3.10 LITIGATION. Except as disclosed on SCHEDULE 3.10 attached hereto, (a)
there is no Claim pending or, to the knowledge of the Stockholder, threatened
(or, to the knowledge of the Stockholder, any facts which could lead to such a
Claim) by, against, affecting or regarding the Business or the Sellers or the
Stockholder or their respective businesses, properties or assets, at law or in
equity, before any federal, state, local or foreign court or any other
governmental or administrative agency or tribunal or any arbitrator or
arbitration panel, and (b) there are no judgments, orders, rulings, charges,
decrees, injunctions, notices of violation or other mandates against or
affecting the Business or the Sellers or the Stockholder with respect to the
businesses, properties or assets of a Seller. Nothing listed on SCHEDULE 3.10,
either individually or when aggregated with other listings on such Schedule,
would reasonably be expected to have a Material Adverse Effect.
3.11 TAXES, EMPLOYEE BENEFITS AND ENVIRONMENTAL.
(a) The Stockholder is not aware of any dispute or Claim concerning
any liability for Taxes of any Seller.
(b) No Seller has a profit sharing, 401(k), disability, medical,
dental, severance pay, vacation pay, sick pay, deferred compensation, incentive
compensation, fringe benefit, stay-with-bonus, change of control agreement, or
other employee benefit plan, program, or agreement (other than stock option
plans), including without limitation, any employee benefit plan as defined in
section 3(3) of ERISA, which is maintained or contributed to by a Seller, or
14
under which such Seller has any liability or contingent liability.
(c) The use and operation by each Seller and by all past owners and
operators, of all facilities and properties used in the business of each Seller
have been, and will be on the Closing Date, in compliance in all material
respects with all Environmental Laws, and no Environmental Action has been
filed, commenced, or, to the knowledge of the Sellers and the Stockholder,
threatened with or against any of them alleging any failure so to comply.
3.12 DISCLOSURE OF MATERIAL INFORMATION. This Agreement (including the
Schedules and Exhibits hereto) does not contain, with respect to each Seller or
the Stockholder, any untrue statement of a material fact or omits to state a
material fact necessary to make the statements therein not misleading in light
of the circumstances under which they were made. There is no fact known to the
Stockholder which has or would reasonably be expected in the future to result in
a Material Adverse Effect and which has not been set forth in this Agreement or
previously disclosed in writing to the Buyer.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF BUYER
Buyer hereby represents and warrants to each Seller and the Stockholder as
follows:
4.1 ORGANIZATION AND QUALIFICATION. Buyer is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware
with full power and authority to own, use or lease its properties and to conduct
its business as such properties are owned, used or leased and as such business
is conducted.
4.2 AUTHORITY. Buyer has the requisite corporate power and authority to
enter into this Agreement and to carry out the transactions contemplated hereby.
The execution, delivery and performance of this Agreement by Buyer have been
duly and validly authorized and approved by all necessary corporate action on
the part of Buyer, and this Agreement constitutes the legal and binding
obligation of Buyer, enforceable against Buyer in accordance with its terms.
Assuming the accuracy of the representations and warranties of the Sellers and
the Stockholder hereunder and to the best knowledge of Buyer, the entering into
of this Agreement by Buyer does not, and the consummation by Buyer of the
transactions contemplated hereby will not, violate the provisions of (a) any
applicable laws of the United States or any other state or jurisdiction in which
Buyer does business, (b) the Charter or By-Laws of Buyer or (c) any provision
of, or result in a default or acceleration of any obligation under, or result in
any change in the rights or obligations of Buyer under, any mortgage, Lien,
lease, agreement, contract, instrument, order, arbitration award, judgment, or
decree to which Buyer is a party or by which Buyer is bound, or to which any
property of Buyer is subject.
4.3 BROKERS. Neither Buyer nor anyone acting on its behalf has engaged,
retained or incurred any liability to any broker, investment banker, finder or
agent or has agreed to pay any brokerage fees, commissions, finder's fees or
other fees with respect to the purchase of
15
Purchased Assets, the issuance of the Consideration Shares, this Agreement or
the transactions contemplated hereby.
4.4 BUYER FINANCIAL STATEMENTS. Attached hereto as SCHEDULE 4.4 are the
following financial statements (collectively the "Buyer Financial Statements"):
unaudited consolidated balance sheets and statements of income, changes in
stockholders' equity and cash flow as of and for the fiscal year ended December
31, 2002 of the Buyer. The Buyer Financial Statements have been prepared in
accordance with GAAP applied on a consistent basis throughout the periods
covered thereby, present fairly the financial condition of the Buyer as of such
dates and the results of operations of the Buyer for such periods, are correct
and complete, and are consistent with the books and records of the Buyer, except
that the Buyer Financial Statements may not contain all footnotes required by
GAAP and are subject to normal year-end audit adjustments.
4.5 FINANCIAL CONDITION. Since the date of the Buyer Financial Statements,
there have been no subsequent events having a material adverse effect on Buyer's
business, results of operations or financial condition. Buyer represents that as
of the date of this Agreement, it currently has in excess of $50 million in a
combination of cash, cash equivalents and amounts committed under investor
subscription agreements.
4.6 ONE CLASS OF STOCK. Buyer has one class of capital stock outstanding,
and Buyer's certificate of incorporation, as amended or restated through the
date hereof, authorizes no class of capital stock senior to the Buyer's Common
Stock in terms of liquidation, dividend or redemption rights.
4.7 LITIGATION. Except as disclosed on SCHEDULE 4.7 attached hereto, (a)
there is no Claim pending or, to the knowledge of the Buyer, threatened (or, to
the knowledge of the Buyer, any facts which could lead to such a Claim) by,
against, affecting or regarding the Buyer or its business, properties or assets,
at law or in equity, before any federal, state, local or foreign court or any
other governmental or administrative agency or tribunal or any arbitrator or
arbitration panel that would reasonably be expected in the future to have a
Material Adverse Effect, and (b) there are no judgments, orders, rulings,
charges, decrees, injunctions, notices of violation or other mandates against or
affecting the Buyer with respect to the business, properties or assets of the
Buyer.
4.8 DISCLOSURE OF MATERIAL INFORMATION. This Agreement (including the
Schedules and Exhibits hereto) does not contain, with respect to the Buyer, any
untrue statement of a material fact or omits to state a material fact necessary
to make the statements therein not misleading in light of the circumstances
under which they were made.
16
ARTICLE V
COVENANTS
5.1 COVENANTS OF THE SELLERS AND THE STOCKHOLDER. Each Seller and the
Stockholder shall keep, perform and fully discharge the following covenants and
agreements:
(a) INTERIM CONDUCT OF BUSINESS. From the date hereof until the
Closing, each Seller shall operate its business consistent with prior practice
immediately before the date hereof and in the ordinary course of business
(except as may be authorized pursuant to this Agreement or as set forth on
SCHEDULE 5.1(a) hereto). Without limiting the generality of the foregoing, from
the date hereof until the Closing, except for transactions contemplated by this
Agreement or expressly approved in writing by Buyer, no Seller shall:
(i) enter into or amend any employment, bonus, severance, or
retirement contract or arrangement, or increase any compensation
payable or to become payable to any person other than in the ordinary
course of business consistent with prior practice;
(ii) purchase, lease or otherwise acquire any real estate or
any interest therein;
(iii) declare, set aside or pay any dividend or make any other
distribution with respect to any Equity Security or authorize for
issuance, issue, sell or deliver any of its own Equity Securities or
split, combine or reclassify any class of Equity Security or redeem or
otherwise acquire, directly or indirectly, any of its Equity
Securities;
(iv) merge or consolidate with or agree to merge or
consolidate with, or purchase or agree to purchase all or
substantially all of the assets of, acquire securities of or otherwise
acquire any Person;
(v) sell, lease or otherwise dispose of or agree to sell,
lease or otherwise dispose of any of its assets, properties, rights or
claims, whether tangible or intangible, except in the ordinary course
of business consistent with prior practice;
(vi) incur any liability, guaranty or obligation (fixed or
contingent) other than in the ordinary course of business consistent
with prior practice or make any investment in excess of $5,000,
whether singly or in the aggregate, in property, plant and equipment
and other items of capital expenditure;
(vii) place or permit to be placed any Lien on any of its
assets or properties, other than statutory Liens arising in the
ordinary course of business;
17
(viii) make or authorize any amendments or changes to its
Charter or By-Laws; or
(ix) abandon any part of its business not abandoned as of the
date hereof.
(b) ACCESS. Each Seller shall, upon reasonable notice, give Buyer and
its representatives full and free access to all properties, assets, books,
contracts, commitments and records of such Seller during reasonable business
hours and shall promptly furnish Buyer with all financial and operating data and
other information as to the history, ownership, Affiliates, business, operations
and properties of such Seller as Buyer may from time to time reasonably request.
(c) TRANSFER OF NECESSARY PERMITS. From and after the date hereof
through to the Closing Date and following the Closing, each Seller will use
reasonable commercial efforts to effect the transfer to Buyer of all of the
Necessary Permits and all other permits, licenses (except the DFCI License
Agreement), and leases which are associated with the Business as presently
conducted, to the extent the same are by their terms transferable.
(d) RETAINED LIABILITIES. From and after the date hereof through to
the Closing Date and following the Closing, each Seller agrees to pay, perform
and fully discharge all of the Retained Liabilities.
(e) SATISFACTION OF CONDITIONS. Each Seller and the Stockholder shall
use their best efforts to accomplish the satisfaction of the conditions
precedent to Closing contained in Section 6.1 herein on or prior to the Closing
Date.
(f) NO SOLICITATION, CONFIDENTIALITY, ETC. Prior to the termination
of this Agreement pursuant to Article VII hereof, no Seller or the Stockholder
will (i) solicit or negotiate with respect to any inquiries or proposals
relating to (x) the possible direct or indirect acquisition of any Equity
Security of any Seller or of all or a portion of the Purchased Assets or
Business or (y) any merger, consolidation, joint venture or business combination
with any Seller or (ii) discuss or disclose either this Agreement or other
confidential information pertaining to any Seller with any Person (except as may
be required by law or except as may be required in connection with the
transactions contemplated by this Agreement to Affiliates, officers, directors,
employees and agents of such Seller or any stockholder) without the prior
written approval of Buyer. Buyer acknowledges that the prior distribution of
material regarding the Sellers to interested parties shall not be deemed to
violate this Section 5.1(g). The Sellers and the Stockholder shall advise such
parties of the existence of this Agreement and shall refrain from entering into
further discussions with such parties concerning the sale of any Seller to the
extent otherwise prohibited by this Section 5.1(g).
(g) ACCURACY OF REPRESENTATIONS AND WARRANTIES. Without the prior
written consent of Buyer, the Stockholder and each Seller will not take any
action from the date hereof to the Closing Date, whether as an officer, director
or stockholder of such Seller or otherwise,
18
that would cause any representation or warranty of such Seller or the
Stockholder contained in this Agreement to become untrue or cause the breach of
any agreement hereof or covenant contained herein. The Stockholder and each
Seller will promptly bring to the attention of Buyer any facts which come to its
attention that would cause any of the representations and warranties of such
Seller or the Stockholder to be untrue or materially misleading in any respect.
(h) TAX MATTERS. The Stockholder shall be responsible for and shall
cause to be prepared and duly filed all Tax Returns relating to Taxes of each
Seller.
5.2 COVENANTS OF BUYER, THE SELLERS AND THE STOCKHOLDER. The parties
hereto hereby agree to keep, perform and fully discharge the following covenants
and agreements:
(a) WAIVER OF COMPLIANCE WITH THE BULK SALES ACT. In connection with
the transactions contemplated hereby, the parties hereby waive compliance with
the provisions of Article 6 of the Uniform Commercial Code - Bulk Transfers and
the Bulk Sales Act and any other applicable United States, Mexican, state or
provincial bulk sales act or statute ("Bulk Sales Acts"). Each Seller shall
remove any and all Liens against the Purchased Assets as a result of payments
made by such Seller to others. Each Seller and the Stockholder, severally but
not jointly, shall indemnify and hold the Buyer harmless from and against any
and all liabilities under the Bulk Sales Acts.
(b) BUY-BACK OPTION. If, within thirty (30) months following the
Closing Date, Buyer has not initiated clinical trials for a Kava Product, then
Kava shall have the option to repurchase the Kava IP from Buyer for the sum of
Seven Hundred Fifty Thousand Dollars ($750,000) in cash (the "Buy-Back Option").
The Buyer shall deliver a written notice to Kava or any of its authorized
assignees or designees within one month after the start of any such clinical
trial for a product derived from the Kava IP. Kava shall be permitted to assign
the Buy-Back Option to the Stockholder or any member or designee of Stockholder
upon providing written notice to Buyer. The Buy-Back Option shall be exercisable
by Kava or any of its authorized assignees or designees for a period of three
(3) months after said thirty (30) month period ends by providing written notice
of exercise to Buyer. If Kava or any of its authorized assignees or designees
fails to provide such notice within such period, the Buy-Back Option shall
terminate and be of no further force or effect. The Buyer agrees to notify Kava,
or its assignee, when this clinical trial requirement has been satisfied.
5.3 ADDITIONAL COVENANTS.
(a) CUSTOMERS AND OTHER BUSINESS RELATIONSHIPS. After the Closing,
Sellers will cooperate with Buyer in its efforts to continue and maintain for
the benefit of Buyer those business relationships of Seller existing prior to
the Closing and relating to the Business to be operated by Buyer after the
Closing, including relationships with lessors, regulatory authorities,
licensors, customers, suppliers and others, and Sellers will use reasonable
commercial efforts to satisfy the Retained Liabilities in a manner that is not
detrimental to any of such relationships. After the Closing, Sellers will refer
to Buyer all inquiries relating to the Business. Neither Seller nor any of its
officers, agents or shareholders shall take any action that would reasonably be
expected to diminish the value of the Purchased Assets after the Closing or that
would interfere
19
with the business of Buyer to be engaged in after the Closing, including
disparaging the name or business of Buyer.
(b) FURTHER ASSURANCES. The parties shall cooperate reasonably with
each other and with their respective representatives in connection with any
steps required to be taken as part of their respective obligations under this
Agreement, and shall (i) furnish upon request to each other such further
information; (ii) execute and deliver to each other such other documents; and
(iii) do such other acts and things, all as the other Party may reasonably
request as is necessary to carry out the intent of this Agreement and the
transactions contemplated hereby.
5.4 COVENANTS OF BUYER. The Buyer hereby agrees to keep, perform and fully
discharge the following covenants and agreements:
(a) PROGRESS REPORTS. Beginning twelve months after the Closing Date
and annually thereafter, Buyer shall submit to Stockholder a progress report
summarizing Buyer's activities related to the development and testing of
products relating to the Kava IP, CG IP and the SinglePixel IP and the obtaining
of governmental approvals necessary for marketing same.
(b) ROYALTY REPORT. After the first commercial sale anywhere in the
world of a Kava Product or CG Product, Buyer shall make quarterly royalty
reports to Stockholder for such Kava Product or CG Product (as the case may be)
no later than forty-five (45) days after the end of each such quarter. Each such
royalty report will cover Buyer's most recently completed calendar quarter and
shall include the units sold, gross revenue and royalties payable by Buyer to
the Sellers, or any of their assignees, itemized by product.
(c) RIGHT TO AUDIT. Buyer shall keep full and accurate books and
records in sufficient detail so that all amounts due and payable to any Seller
or the Stockholder hereunder can be properly determined. Such books and records
shall be preserved for at least three years from the date of entry to which they
pertain. Such books and records shall be open to inspection at any reasonable
time during business hours not more often than once each calendar year by an
independent certified public accountant selected by the Stockholder for the sole
purpose of verifying reports and payments hereunder. Such independent certified
public accountant shall report the findings of his or her inspection to the
Stockholder but shall under no circumstances report any information other than
information related to the accuracy of such reports and payments. All fees and
expenses of such inspection shall be borne by the Stockholder; provided that, if
such inspection determines that gross revenue reported to Stockholder pursuant
to Section 5.4(b) of this agreement is understated in any quarter by five
percent (5%) or more, then Buyer shall bear all the fees and expenses of such
inspection.
ARTICLE VI
CLOSING CONDITIONS
6.1 CONDITIONS TO OBLIGATIONS OF BUYER. The obligations of Buyer to
consummate this Agreement and the transactions contemplated hereby are subject
to the fulfillment, prior to or at
20
the Closing, of the following conditions precedent, subject to a bring-down of
the disclosure schedules.
(a) REPRESENTATIONS, WARRANTIES AND COVENANTS. Each of the
representations and warranties of the Sellers and the Stockholder contained in
this Agreement shall remain true and correct in all material respects at the
Closing Date as fully as if made on the Closing Date (other than the
representations and warranties that contain an express materiality
qualification, which shall be true and correct in all respects); each Seller and
the Stockholder shall have performed in all material respects, on or before the
Closing Date, all of its respective obligations under this Agreement and the
other Purchase Documents which by the terms thereof are to be performed on or
before the Closing Date; and each Seller and the Stockholder shall have
delivered to Buyer an Officer's Certificate dated the Closing Date of such
Seller and the Stockholder to such effect.
(b) PURCHASE PERMITTED BY APPLICABLE LAWS; LEGAL INVESTMENT. Buyer's
purchase of and payment for the Purchased Assets (a) shall not be prohibited by
any applicable law or governmental order, rule, ruling, regulation, release or
interpretation (b) shall not constitute a fraudulent or voidable conveyance
under any applicable law and (c) shall be permitted by all applicable laws,
statutes, ordinances, regulations and rules of the jurisdictions to which Buyer
is subject.
(c) PROCEEDINGS SATISFACTORY. All proceedings taken in connection
with the purchase and sale of the Purchased Assets, all of the other Purchase
Documents and all documents and papers relating thereto, shall be in form and
substance reasonably satisfactory to Buyer.
(d) CONSENTS - PERMITS. Each Seller shall have received (and there
shall be in full force and effect) all material consents (except with respect to
the DFCI License Agreement), approvals, licenses, permits, orders and other
authorizations of, and shall have made (and there shall be in full force and
effect) all such filings, registrations, qualifications and declarations with,
any Person pursuant to any applicable law, statute, ordinance regulation or rule
or pursuant to any agreement, order or decree to which such Seller is a party or
to which it is subject, in connection with the transactions contemplated by this
Agreement and the sale of the Purchased Assets.
(e) CORPORATE DOCUMENTS. Each Seller shall have delivered to Buyer:
(i) an Officer's Certificate of the Secretary of each Seller
and the managing member of the Stockholder certifying (x) the incumbency and
genuineness of signatures of all officers of the Stockholder and the Sellers, as
the case may be, executing this Agreement, any document delivered by the
Stockholder and the Sellers at the Closing and any other document, instrument or
agreement executed in connection herewith, (y) the truth and correctness of
resolutions of the Sellers and the Stockholder authorizing the entry by the
Sellers and the Stockholder into this Agreement and the transactions
contemplated hereby and (z) the truth, correctness and completeness of the
By-Laws of the Sellers and the Stockholder;
21
(ii) the certificate of formation of the Stockholder and the
Charter of each Seller certified as of a recent date by the Secretary of State
of the State of Delaware; and
(iii) certificates of corporate good standing and legal
existence of each of the Stockholder and each Seller as of a recent date from
the Secretary of State of the State of Delaware.
(f) BILLS OF SALE. Each Seller shall have executed and delivered to
the Buyer a Xxxx of Sale in the form of EXHIBIT A attached hereto.
(g) INSTRUMENTS OF ASSUMPTION. The Buyer and each Seller shall have
executed and delivered an Instrument of Assumption in the form of EXHIBIT B
attached hereto.
(h) TRANSFER OF NECESSARY PERMITS. All of the Necessary Permits
(except any Permit with respect to the DFCI License Agreement) shall have been
transferred to or obtained by Buyer on or before the Closing Date
(i) NON-COMPETITION AGREEMENTS. Each Seller and the Stockholder shall
have executed and delivered to Buyer non-competition, non-solicitation and
non-disclosure agreements in substantially the form of EXHIBIT C attached hereto
(the "Non-Competition Agreements").
(j) PATENT ASSIGNMENTS. Each Seller shall have executed and delivered
to Buyer a patent assignment in substantially the form of EXHIBIT D attached
hereto (the "Patent Assignments").
6.2 CONDITIONS TO OBLIGATIONS OF THE SELLERS AND THE STOCKHOLDER. The
obligations of each Seller and the Stockholder to consummate this Agreement and
the transactions contemplated hereby are subject to the fulfillment, prior to or
at the Closing, of the following conditions precedent:
(a) REPRESENTATIONS AND WARRANTIES. Each of the representations and
warranties of Buyer in this Agreement shall remain true and correct in all
material respects at the Closing Date as fully as if made on the Closing Date
(other than the representations and warranties that contain an express
materiality qualification, which shall be true and correct in all respects, and
Buyer shall, on or before the Closing Date, have performed, in all material
respects, all of its obligations under this Agreement and the Other Purchase
Documents which by the terms thereof are to be performed by it on or before the
Closing Date; and Buyer shall have delivered an Officer's Certificate to counsel
for the Sellers dated the Closing Date to such effect.
(b) LICENSE GRANT BY BUYER. Buyer shall have executed and delivered
to Kava an exclusive, perpetual, assignable, fully paid-up, royalty-free license
to use the Kava IP solely for liquid beverages (including "shooters") in
substantially the form of EXHIBIT E attached hereto (the "Kava Pharmaceutical
License Agreement").
22
ARTICLE VII
TERMINATION
7.1 TERMINATION OF AGREEMENT. This Agreement and the transactions
contemplated hereby may (at the option of the party having the right to do so)
be terminated at any time on or prior to the Closing Date by:
(a) MUTUAL CONSENT. By mutual written consent of Buyer and a Seller;
(b) COURT ORDER. By Buyer, a Seller or the Stockholder if any court
of competent jurisdiction shall have issued an order pursuant to the request of
a third party restraining, enjoining or otherwise prohibiting the consummation
of the transactions contemplated by this Agreement;
(c) FAILURE TO CLOSE BY JANUARY 31, 2004. By Buyer or the Stockholder
if the transactions contemplated hereby shall not have been consummated on or
before January 31, 2004, PROVIDED, HOWEVER, that such right to terminate this
Agreement shall not be available to any party whose failure to fulfill any
obligation of this Agreement has been the cause of, or resulted in, the failure
of the transactions contemplated hereby to be consummated on or before such
date;
(d) TERMINATION BY STOCKHOLDER. By the Stockholder upon notice to
Buyer at any time prior to the Closing Date, if (i) a condition to the
performance of a Seller set forth in Section 6.2 hereof shall not be fulfilled
at the time specified for the fulfillment thereof, (ii) a material default under
or a material breach of this Agreement shall be made by Buyer, or (iii) any
representation or warranty set forth in this Agreement or in any instrument
delivered by Buyer pursuant hereto shall be materially false or misleading; or
(e) TERMINATION BY BUYER. By Buyer by notice to a Seller at any time
prior to the Closing Date, if (i) a condition to the performance of Buyer set
forth in Section 6.1 hereof shall not be fulfilled at the time specified for the
fulfillment thereof, (ii) a default under or a breach of this Agreement shall be
made by such Seller or the Stockholder, or (iii) any representation set forth in
this Agreement or in any instrument delivered by such Seller or the Stockholder
pursuant hereto shall be false or misleading.
7.2 EFFECT OF TERMINATION AND RIGHT TO PROCEED. If this Agreement is
terminated pursuant to this Article VII, then except as provided below, all
further obligations of Buyer, such Seller(s) and the Stockholder under this
Agreement shall terminate without further liability of Buyer or any Affiliate
thereof to the Stockholder or such Seller(s) or of the Stockholder or such
Seller(s) to Buyer or any Affiliate thereof, except with respect to the
obligations set forth in Sections 7.1, 9.1, 9.2 and 9.12, and except, in the
case of termination pursuant to Section 7.1(d) or Section 7.1(e), as to
liability for misrepresentation, breach or default in connection with any
warranty, representation, covenant or obligation given, occurring or arising to
the date of termination. In addition, anything in this Agreement to the contrary
notwithstanding, if any of the conditions to obligations specified in Sections
5.1, 5.2 or 5.3
23
hereof have not been satisfied, Buyer, in addition to any other rights which it
may have, shall have the right to waive its rights to have such conditions
satisfied and elect to proceed with the transactions contemplated hereby and, if
any of the conditions to the obligations of a Seller and the Stockholder
specified in Section 5.4 hereof have not been satisfied, such Seller and the
Stockholders in addition to any other rights which may be available to them,
shall have the right to waive their rights to have such conditions satisfied and
elect to proceed with the transactions contemplated hereby.
ARTICLE VIII
INDEMNIFICATION
8.1 SURVIVAL OF REPRESENTATIONS AND WARRANTIES. Each and every such
representation and warranty set forth in this Agreement shall survive until the
first anniversary of the Closing Date, except for representations and warranties
relating to the Intellectual Property, which shall survive until the second
anniversary of the Closing Date.
8.2 INDEMNIFICATION BY THE SELLERS AND THE STOCKHOLDER. Each Seller and
the Stockholder shall indemnify, defend and hold Buyer, its officers, directors,
employees, owners, agents and Affiliates, harmless from and in respect of any
and all losses, damages, costs and expenses of any kind and nature whatsoever
(including, without limitation, interest and penalties, reasonable expenses of
investigation and court costs, reasonable attorneys' fees and disbursements and
the reasonable fees and disbursements of other professionals) which may be
sustained or suffered by any of them (collectively, "Losses"), arising out of,
resulting from or pertaining to any breach or inaccuracy of any representation
or warranty or the breach of or failure to perform any warranty, covenant,
undertaking or other agreement of a Seller or the Stockholder contained in this
Agreement or any other Purchase Document; PROVIDED, HOWEVER, that the maximum
liability of a Seller and the Stockholder pursuant to this Section 8.2 shall be
limited to the Purchase Price and all other payments received by such Seller and
the Stockholder hereunder.
8.3 INDEMNIFICATION BY BUYER. Buyer shall indemnify, defend and hold each
of the Sellers and the Stockholder, their respective officers, directors,
employees, consultants, owners, agents and Affiliates, harmless from and in
respect of any and all Losses which may be sustained or suffered by any of them
arising out of or resulting from any breach or inaccuracy of any representation
or warranty or the breach of or failure to perform any warranty, covenant,
undertaking or other agreement of Buyer contained in this Agreement or any other
Purchase Document.
8.4 MINIMUM INDEMNIFICATION; MATERIALITY. Notwithstanding anything to the
contrary contained herein, no party hereto shall be entitled to recover from any
other party unless and until the total of all claims for indemnity or damages
with respect to any inaccuracy or breach of any such representations or
warranties or breach of or default in the performance of any covenants,
undertakings or other agreements, whether such claims are brought under this
Article VIII or otherwise, exceeds $50,000, in which case such parties shall be
entitled to recover the total amount of such claims.
24
8.5 NOTICE AND OPPORTUNITY TO DEFEND. If there occurs an event which a
party asserts is an indemnifiable event pursuant to Section 8.2 or 8.3, the
parties seeking indemnification shall promptly notify the other parties
obligated to provide indemnification (collectively, the "Indemnifying Party").
If such event involves (a) any Claim or (b) the commencement of any action, suit
or proceeding by a third person, the party seeking indemnification will give
such Indemnifying Party prompt written notice of such Claim or the commencement
of such action, suit or proceeding, PROVIDED, HOWEVER, that the failure to
provide prompt notice as provided herein will relieve the Indemnifying Party of
its obligations hereunder only to the extent that such failure prejudices the
Indemnifying Party hereunder. In case any such action, suit or proceeding shall
be brought against any party seeking indemnification and it shall notify the
Indemnifying Party of the commencement thereof, the Indemnifying Party shall be
entitled to participate therein and, to the extent that it desires to do so, to
assume the defense thereof, with counsel reasonably satisfactory to such party
seeking indemnification and, after notice from the Indemnifying Party to such
party seeking indemnification of such election so to assume the defense thereof,
the Indemnifying Party shall not be liable to the party seeking indemnification
hereunder for any attorneys' fees or any other expenses, in each case
subsequently incurred by such party, in connection with the defense of such
action, suit or proceeding. The party seeking indemnification agrees to
cooperate fully with the Indemnifying Party and its counsel in the defense
against any such action, suit or proceeding. In any event, the party seeking
indemnification shall have the right to participate at its own expense in the
defense of such action, suit or proceeding. In no event shall an Indemnifying
Party be liable for any settlement or compromise effected without its prior
consent. If, however, the party seeking indemnification refuses its consent to a
BONA FIDE offer of settlement which the Indemnifying Party wishes to accept
(which must include the unconditional release of the parties seeking
indemnification from all liability with respect to the Claim at issue), the
party seeking indemnification may continue to pursue such matter, free of any
participation by the Indemnifying Party, at the sole expense of the party
seeking indemnification. In such event, the obligation of the Indemnifying Party
to the party seeking indemnification shall be equal to the lesser of (i) the
amount of the offer or settlement which the party seeking indemnification
refused to accept plus the costs and expenses of such party prior to the date
the Indemnifying Party notifies the party seeking indemnification of the offer
of settlement and (ii) the actual out-of-pocket amount the party seeking
indemnification is obligated to pay as a result of such party's continuing to
pursue such matter.
ARTICLE IX
MISCELLANEOUS
9.1 FEES AND EXPENSES. Each of the parties hereto will pay and discharge
its own expenses and fees in connection of with the negotiation of and entry
into this Agreement and the consummation of the transactions contemplated
hereby.
9.2 NOTICES. All notices, requests, demands, consents and communications
necessary or required under this Agreement or any other Purchase Document shall
be made in the manner specified, or, if not specified, shall be delivered by
hand or sent by registered or certified mail, return receipt requested, or by
telecopy (receipt confirmed) to:
25
if to Buyer:
Synta Pharmaceuticals Corp.
00 Xxxxxxxx Xxx.
Xxxxxxxxx, XX 00000
Attention: Chief Executive Officer
Facsimile Transmission Number: (000) 000-0000
with a copy to:
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Xxx Xxxxxxxxx Xxxxxx
Xxxxxx, XX 00000
Attention: Xxxxxxx Xxxxxx, Esq.
Facsimile Transmission Number: (000) 000-0000
if to CG, Kava or SinglePixel:
Peregrine Financial Corporation
00 Xxxxx Xxxxxx
Xxxxxx, XX 00000
Attention: Xxxx Xxxxxxxxx
Facsimile Transmission Number: (000) 000-0000
with a copy to:
Xxxxx, Xxxxxxx & Xxxxxxxxx, LLP
000 Xxxx Xxxxxx
Xxxxxx, XX 00000
Attention: Xxxxx Xxxx, Esq.
Facsimile Transmission Number: (000) 000-0000
if to Stockholder:
CMAC, LLC
00 Xxxxx Xxxxxx
Xxxxxx, XX 00000
Attention: Xxxx Xxxxxxxxx
Facsimile Transmission Number: (000) 000-0000
with a copy to:
Xxxxx, Xxxxxxx & Xxxxxxxxx, LLP
000 Xxxx Xxxxxx
Xxxxxx, XX 00000
Attention: Xxxxx Xxxx, Esq.
Facsimile Transmission Number: (000) 000-0000
26
All such notices, requests, demands, consents and other communications
shall be deemed to have been duly given or sent two (2) days following the date
on which mailed, or on the date on which delivered by hand or by facsimile
transmission (receipt confirmed), as the case may be, and addressed as
aforesaid.
9.3 SUCCESSORS AND ASSIGNS. Except as otherwise expressly set forth
herein, all covenants and agreements set forth in this Agreement and made by or
on behalf of any of the parties hereto shall bind and inure to the benefit of
the successors and assigns of such party, whether or not so expressed, except
that the Sellers and the Stockholder may not assign or transfer, other than to
the Stockholder or any Affiliate of Stockholder, any of their respective rights
or obligations under this Agreement without the consent in writing of Buyer.
9.4 COUNTERPARTS, ETC. This Agreement may be executed in any number of
counterparts and by the different parties hereto on separate counterparts, each
of which when so executed and delivered shall be an original, but all of which
together shall constitute one and the same instrument, and it shall not be
necessary in making proof of this Agreement to produce or account for more than
one such counterpart. The headings of the sections and paragraphs of this
Agreement have been inserted for convenience of reference only and shall not be
deemed to be part of this Agreement. If any one or more of the provisions
contained herein, or the application thereof in any circumstances, is held
invalid, illegal or unenforceable in any respect for any reason in any
jurisdiction, the validity, legality and enforceability of any such provision in
every other respect and of the remaining provisions hereof shall not be in any
way impaired or affected, it being intended that each of parties' rights and
privileges shall be enforceable to the fullest extent permitted by law, and any
such invalidity, illegality and unenforceability in any jurisdiction shall not
invalidate or render unenforceable such provision in any other jurisdiction.
9.5 TAX MATTERS.
(a) Each Seller will timely file all federal, state, local and
foreign tax reports and returns for any period which ends on or prior to the
Closing Date and which are required to be filed to reflect the operations of
such Seller. All such reports and returns shall be submitted to Buyer for review
at least thirty (30) days prior to filing such reports and returns. Buyer shall
be entitled to participate in the preparation of such reports and returns. All
such reports and returns will be prepared and filed using tax accounting methods
and principles which are substantially consistent with those used in the returns
and reports of taxes for such Seller for preceding tax periods unless Buyer
agrees otherwise. Any item of income, deduction or credit to be included in any
such tax return or report shall be based on the permanent records (including
work papers) of such Seller. Buyer shall prepare and file on behalf of such
Seller all federal, state, local and foreign tax reports and returns for any
period which ends after the Closing Date and which are required to be filed to
reflect the operations of such Seller attributable to a period prior to the
Closing Date.
(b) All refunds of taxes attributable to any or all years or periods
(or portions thereof) ending prior to the Closing Date or attributable to any
taxable year or period which ends at or after the Closing Date, to the extent
that the refund is attributable to the operations of such
27
Seller up to the Closing Date (as determined on the basis of the permanent
records of such Seller), shall belong to and be retained by such Seller.
(c) The parties hereto shall, and shall cause such Seller to, provide
such necessary information as any other party hereto may reasonably request in
connection with the preparation of such parties' Tax Returns, or to respond to
or contest any audit, prosecute any claim for refund or credit or otherwise
satisfy any requirements relating to Taxes of such Seller.
(d) Each Seller shall pay all real property transfer Taxes, sales
Taxes, stock transfer Taxes, documentary stamp Taxes, recording charges and
other similar Taxes resulting from, arising under or in connection with the
transfer of the Purchased Assets or any other related transaction under the
Agreement.
(e) The obligations of each Seller set forth in the Agreement
relating to Taxes shall, except as otherwise agreed in writing, be unconditional
and absolute and shall remain in effect without limitation as to time or amount
of recovery by Buyer until thirty (30) days after the expiration of the
applicable statute of limitations governing the Taxes to which such obligations
relate (after giving effect to any agreement extending or tolling such statute
of limitations).
9.6 GOVERNING LAW. THIS AGREEMENT, INCLUDING THE VALIDITY HEREOF AND THE
RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER, SHALL BE CONSTRUED IN
ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE COMMONWEALTH OF
MASSACHUSETTS
APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED ENTIRELY IN SUCH STATE (WITHOUT
GIVING EFFECT TO THE CONFLICTS OF LAWS PROVISIONS THEREOF).
9.7 ENTIRE AGREEMENT. This Agreement, including the Schedules and Exhibits
referred to herein, is complete, and all promises, representations,
understandings, warranties and agreements with reference to the subject matter
hereof, and all inducements to the making of this Agreement relied upon by all
the parties hereto, have been expressed herein or in said Schedules or Exhibits.
This Agreement, including the Schedules and Exhibits referred to herein,
constitute the entire agreement between the parties with respect to the subject
matter hereof and supersedes all prior agreements, understandings and
negotiations, both written and oral, between the parties with respect to the
subject matter hereof. None of the provisions of this Agreement, including the
Schedules and Exhibits referred to herein, is intended to confer upon any Person
other than the parties hereto any rights or remedies hereunder. This Agreement
may not be amended except by an instrument in writing signed on behalf of each
Seller, Buyer and the Stockholder.
[Remainder of Page Intentionally Left Blank]
28
IN WITNESS WHEREOF the parties hereto have executed this
Asset Purchase
Agreement under seal as of the date first set forth above.
ATTEST:
SYNTA PHARMACEUTICALS CORP.
/s/ XXXXX X. XXXXXX By: /s/ XXXX XXXXXXX
----------------------- -----------------------
Chief Executive Officer
ATTEST: CANCER GENOMICS, INC.
By: /s/ XXXX XXXXXXXXX
---------------------------- -----------------------
Treasurer
ATTEST: KAVA PHARMACEUTICALS, INC.
By: /s/ XXXX XXXXXXXXX
---------------------------- -----------------------
Treasurer
ATTEST: SINGLEPIXEL BIOMEDICAL, INC.
By: /s/ XXXX XXXXXXXXX
---------------------------- -----------------------
Treasurer
ATTEST: CMAC, LLC
By: /s/ XXXX XXXXXXXXX
---------------------------- -----------------------
Treasurer
29
EXHIBIT A
FORM OF XXXX OF SALE
KNOW ALL PERSONS THAT_____________, a________corporation (the "Seller").
acting pursuant to that certain
Asset Purchase Agreement (the "Agreement"),
dated and effective as of____________, by and between the Seller and
Synta
Pharmaceuticals Corp., a Delaware corporation (the "Buyer"), for consideration
specified in the Agreement, the receipt and sufficiency of which are hereby
acknowledged, does hereby bargain, sell, transfer, assign and deliver unto the
Buyer all of the Purchased Assets but specifically excluding the Retained
Assets. All Capitalized terms used but not defined herein shall have the
meanings set forth in the Agreement.
The Purchased Assets shall include the following:
[TO BE COMPLETED]
TO HAVE AND TO HOLD, all and singular, the Purchased Assets hereby
assigned, transferred, and delivered unto Buyer, its successors and assigns, for
its own use and behalf forever.
The representations and warranties of the Seller and the Buyer set forth in
the Agreement are hereby incorporated herein by reference and made a part
hereof. The indemnification obligations of the parties set forth in Article VIII
of the Agreement shall, as provided and subject to the limitations contained in
the Agreement, survive the execution and delivery of this Xxxx of Sale and the
consummation of the transactions effected hereby and thereby. Nothing contained
herein is intended to supercede the covenants, representations and warranties
regarding the Purchased Assets contained in the Agreement, which representations
and warranties shall survive the execution and delivery of this Xxxx of Sale as
set forth in the Agreement.
This Xxxx of Sale and the Agreement (including the schedules and exhibits
thereto) constitute the entire agreement between the parties in connection with
the Purchased Assets and may be amended only by a writing signed by an
authorized representative of each party. This Xxxx of Sale shall be binding upon
and shall inure to the benefit of the parties hereto and their respective legal
representatives, successors and permitted assigns.
This Xxxx of Sale shall be governed by and construed in accordance with the
laws of the State of Delaware to the full extent permitted by applicable law,
without giving effect to the conflict of laws principles thereof.
All capitalized terms used herein and not otherwise defined shall have the
meanings ascribed to them in the Agreement. The use of any singular term shall
include the plural and vice versa.
The Seller hereby covenants and agrees that it will, at the request of the
Buyer, execute and deliver such other instruments of conveyance, assignment and
transfer and take such other action as Buyer may reasonably request to vest in
Buyer the Company's entire right, title and interest in
Exh. A-1
and to the Purchased Assets being transferred hereby, provided that Buyer shall
bear the reasonable and documented costs in connection with the taking of such
actions and the execution and delivery of such documents.
[SIGNATURE PAGE FOLLOWS]
Exh. A-2
IN WITNESS WHEREOF, Seller has executed this Xxxx of Sale dated and
effective as of the ____day of _________,2003.
SELLER:
[NAME]
BY:
-------------------------
Name:
Title:
Exh. A-3
EXHIBIT B
FORM OF INSTRUMENT OF ASSUMPTION
This INSTRUMENT OF ASSUMPTION dated__________is executed and delivered by
___________________, a _______corporation, (hereinafter referred to as
"Seller"), to
SYNTA PHARMACEUTICALS CORP., a Delaware corporation (hereinafter
referred to as "Buyer"). All capitalized words and terms used in this Instrument
of Assumption and not defined herein shall have the respective meanings ascribed
to them in that certain
Asset Purchase Agreement, dated as of___________(the
"Agreement"), among Buyer, Seller and the other parties named therein.
WHEREAS, pursuant to the Agreement, the Seller has agreed to sell, convey,
assign, transfer and deliver to the Buyer all of the Purchased Assets;
WHEREAS, in consideration therefore, the Agreement requires the Purchaser
to assume the Assumed Liabilities;
NOW, THEREFORE, for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Purchaser hereby agrees as
follows:
1. The Seller hereby assigns to the Buyer, and the Buyer hereby assumes
and agrees to perform, pay and discharge when due all of the Assumed
Liabilities.
2. Nothing herein shall be deemed to deprive the Buyer of any defenses,
set-offs or counterclaims which the Seller may have had or which the Buyer shall
have with respect to any of the obligations, liabilities and commitments hereby
assumed (the "Defenses and Claims"). The Seller hereby transfers, conveys and
assigns to the Buyer all Defenses and Claims.
3. This instrument shall be governed by and construed in accordance with
the laws of the Commonwealth of
Massachusetts.
4. This instrument may be executed in one or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument. Delivery by telecopy by a party of a copy of an
executed counterpart hereof shall constitute execution and delivery hereof by
such party.
5. This instrument shall inure to the benefit of, and shall be binding
upon, Buyer and Seller and their respective successors and assigns.
6. Any amendments to this instalment shall be made only in writing,
signed by the parties hereto.
Exh. B-1
IN WITNESS WHEREOF, the undersigned, have executed this instrument as of
the date first written above.
Seller:
---------------------
By:
---------------------------
Name:
Title:
BUYER:
SYNTA PHARMACEUTICALS CORP.
By:
---------------------------
Name:
Title:
Exh. B-2
EXHIBIT C
FORM OF NON-COMPETITION, NON-SOLICITATION AND
CONFIDENTIALITY AGREEMENT
NON-COMPETITION, NON-SOLICITATION AND CONFIDENTIALITY AGREEMENT (the
"Agreement"), dated as of [____________], 2003, by and among
Synta
Pharmaceuticals Corp., a Delaware corporation ("Buyer"), [____________], Inc., a
Delaware corporation (the "Seller"), and CMAC, LLC, a Delaware limited liability
company ("Stockholder"). Each capitalized term used but not defined herein shall
have the meaning set forth in the
Asset Purchase Agreement (defined below).
WITNESSETH:
WHEREAS, the Buyer, the Seller and the Stockholder have entered into a
Asset Purchase Agreement, dated as of [____________], 2003 (the "
Asset Purchase
Agreement"), pursuant to which the Seller shall sell to the Buyer and the Buyer
shall purchase from the Seller certain assets of the Seller as more specifically
set forth therein;
WHEREAS, the Stockholder, by virtue of, among other things, the
Stockholder's status as the majority stockholder of the Seller, is in possession
of certain confidential and proprietary information relating to the Seller;
WHEREAS, the Seller is engaged in the business of [____________] (the
"Business");
WHEREAS, it is a condition to the obligations of the Buyer under the
Asset
Purchase Agreement that the Seller and Stockholder enter into this Agreement;
and
WHEREAS, the Seller and Stockholder have agreed to enter into this
Agreement in consideration of the Buyer's acts as contemplated by the Asset
Purchase Agreement.
NOW, THEREFORE, in consideration of the foregoing and the mutual promises
herein contained and other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the Buyer, the Seller and the
Stockholder agree as follows:
1. MATERIALITY. The Seller and Stockholder hereby agree that a portion of
the Purchase Price (as defined in the Asset Purchase Agreement) is being paid
to protect the goodwill of the Seller, which includes the confidential
information, trade secrets and know-how of the Seller. Accordingly, the Seller
and Stockholder hereby agree that the covenants set forth in this Agreement
form a material and substantial part of the transactions contemplated by the
Asset Purchase Agreement to protect the confidential information, trade
secrets and know-how of the Seller and that the Seller and Stockholder have
entered into this Agreement in order to induce the Buyer to enter into the
Asset Purchase Agreement.
2. STOCKHOLDER AND SELLER NON-COMPETE.
(a) The Seller and Stockholder acknowledge and agree with respect to the
Seller that the Business of the Seller is conducted around the world (the
"Territory"), and that the Seller's
Exh. C-1
reputation and goodwill are an integral part of its business success throughout
the Territory. If the Stockholder or Seller deprives the Buyer of any of the
Seller's goodwill or in any manner utilizes its reputation and goodwill in
competition with the Business, the Buyer will be deprived of the benefits it has
bargained for pursuant to the Asset Purchase Agreement. Accordingly, as an
inducement for the Buyer to enter into the Asset Purchase Agreement, the Seller
and Stockholder agree that during the period beginning on the Closing Date and
ending on the second anniversary of the Closing Date (the "Non-Competition
Period") the Seller and Stockholder shall not (and shall cause their Affiliates
not to), without the Buyer's prior written consent, directly or indirectly, own,
manage, operate, join, control or participate in the ownership, management,
operation or control of, or be connected as a director, officer, employee,
partner, consultant or otherwise with, or permit the Seller's or Stockholder's
name to be used by or in connection with, any Person that, directly or
indirectly, competes with the Buyer in the Business (as conducted by the Buyer)
in the Territory (any such Person being a "Competitive Business").
(b) Notwithstanding anything to the contrary in subclause (a), the
Stockholder may be a passive owner (which shall not prohibit the exercise of any
rights as a shareholder) of not more than 5% of the outstanding stock of any
class of any Competitive Business.
3. NON-SOLICITATION. During the period beginning on the Closing Date and
ending on the second anniversary of the Closing Date (the "Restricted
Period"), the Seller and Stockholder shall not (and shall cause their
Affiliates not to) (i) solicit, raid, entice, induce or contact, or attempt to
solicit, raid, entice, induce or contact, any Person that is a customer of the
Buyer[Business] immediately after the Closing (as defined in the Asset
Purchase Agreement) to become a customer of any other Person for services
which are the same as, or competitive with, those services sold, rendered or
otherwise made available to customers by the Seller as of the Closing Date or
by the Buyer on and after the Closing Date, or approach any such Person for
such purpose or authorize the taking of such actions by any other Person or
assist or participate with any such Person in taking such action, or (ii)
solicit, raid, entice, induce or contact, or attempt to solicit, raid, entice,
induce or contact any Person that currently is or at any time during the
Restricted Period shall be (or, in the case of termination is at the time of
termination), an employee, agent or consultant of or to the Seller or the
Buyer, as the case may be, to do anything from which the Seller or Stockholder
is restricted by reason of this SECTION 3, and the Seller and Stockholder
shall not (and shall cause the their Affiliates not to) approach any such
employee, agent or consultant for such purpose or authorize or participate in
the taking of such Person in taking such action. The term "customer" shall
include: (i) customers of the Seller or Buyer existing immediately prior to
the Closing; (ii) customers that have used the products and services of the
Seller within the one (1) year period prior to the Closing Date; and (iii) any
prospective customers identified as such by the BuyerSeller prior to the
Closing Date.
4. NON-DISPARAGEMENT. During the Restricted Period, the Seller and
Stockholder shall not make any statement or other communication that impugns
or attacks the reputation or character of the Business or damages the goodwill
of the BuyerSeller or theits Business, take any action that would interfere
with any contractual or customer or supplier relationships conveyed to the
Buyer as part of the Purchased Assets, including but not limited to any
Exh. C-2
action that would result in a diminution of business, or otherwise take any
action that is detrimental to the best interests of the Business or the
Purchased Assets.
5. CONFIDENTIALITY. The Seller and Stockholder covenant and agree that
neither the Seller nor Stockholder shall at any time, directly or indirectly,
disclose any secret or confidential information that the Seller or Stockholder
has about the other, including information that the Seller or Stockholder may
learn or has learned by reason of prior ownership of the Purchased Assets or
the Stockholder's ownership of Seller securities, or use any such information
in a manner detrimental to the interests of the Buyer, unless (i) such
information becomes known to the public generally through no fault of the
Seller and Stockholder, (ii) disclosure is required by law or the order of any
governmental authority under color of law; or (iii) the disclosing party
reasonably believes that such disclosure is required in connection with the
defense of a lawsuit against the disclosing party, provided that prior to
disclosing any information pursuant to clause (i)-(iii) above, the Seller
and/or Stockholder shall give prior written notice thereof to the Buyer and
provide Buyer with the opportunity to contest such disclosure and shall
cooperate with the efforts to prevent such disclosure. The Seller and
Stockholder acknowledge that the right to maintain the secrecy of the trade
secrets, know-how and confidential information related to the Purchased Assets
constitutes a proprietary right that the Buyer is entitled to protect and that
the disclosure, or improper use, of the trade secrets, know-how or the
confidential information of the Seller through the Closing Date or related to
the Purchased Assets by the Seller and/or Stockholder will cause irreparable
harm to the Buyer. The term "confidential information" includes, without
limitation, information not previously disclosed to the public or to the
trade, including without limitation information about Seller's products,
facilities, methods, trade secrets and other intellectual property, software,
source code, systems, procedures, manuals, confidential reports, product price
lists, customer lists, financial information (including the revenues, costs or
profits associated with any of the Seller's products), business plans,
prospects or opportunities.
6. ENFORCEABILITY.
(a) The Seller and Stockholder agree that a breach of the covenants
contained in this Agreement will cause irreparable damage to the Buyer, the
exact amount of which will be difficult to ascertain, and that the remedies at
law (including, without limitation, a claim for monetary damages) for any such
breach will be inadequate. In the event of the breach or a threatened breach by
the Seller or Stockholder of any of the provisions of this Agreement, the Buyer,
in addition and supplementary to other rights and remedies existing in its
favor, may apply to any court of law or equity of competent jurisdiction for
specific performance and/or injunctive or other relief in order to enforce or
prevent any violations of the provisions hereof (without posting a bond or other
security). In addition, in the event of an actual breach or violation by the
Seller or Stockholder of this Agreement, the Non-Competition Period and the
Restricted Period with respect to the Seller or Stockholder, as the case may be,
shall be tolled until such breach or violation has been duly cured.
(b) Whenever possible, each provision of this Agreement shall be
interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Agreement is held to be invalid, illegal or
unenforceable in any respect under any applicable law or rule in
Exh. C-3
any jurisdiction, such invalidity, illegality or unenforceability will not
affect any other provision or any other jurisdiction, but this Agreement shall
be reformed, construed and enforced in such jurisdiction as if such invalid,
illegal or unenforceable provision had never been contained herein. More
specifically, if any court determines that the non-competition restrictions set
forth in SECTION 2 of this Agreement are unenforceable by reason of extending
the Non-Competition Period for too great a period of time, over too great a
geographical scope or otherwise, the parties to this Agreement specifically
agree and authorize such court to rewrite this Agreement to reflect the maximum
time, geographical and/or other restrictions permitted under applicable law to
be reasonable and enforceable.
7. REASONABLE RESTRAINT. The parties agree that the foregoing covenants
impose a reasonable restraint on the Seller and Stockholder in light of the
activities and business of the parties on the date of execution of this
Agreement and the transactions contemplated in the Asset Purchase Agreement;
but it is also the intent that such covenants be construed and enforced in
accordance with the changing activities and business of the Buyer throughout
the term of this Agreement.
8. COUNTERPARTS. This Agreement may be executed in counterparts, any one
of which need not contain the signatures of more than one party, but all such
counterparts taken together will constitute one and the same instrument.
Signatures may be exchanged by telecopy and each party to this Agreement
agrees that it will be bound by its own telecopied signature and that it
accepts the telecopied signatures of the other parties to this Agreement.
9. CAPTIONS. The captions used in this Agreement are for convenience of
reference only, do not constitute a part of this Agreement and will not be
deemed to limit, characterize or in any way affect any provision of this
Agreement. All provisions of this Agreement will be enforced and construed as
if no caption had been used in this Agreement.
10. BINDING EFFECT; AMENDMENT. This Agreement shall be binding upon and
shall inure to the benefit of the parties hereto and their respective heirs,
legal representatives, successors and permitted assigns. Neither the Seller
nor Stockholder may assign its rights or obligations under this Agreement. The
rights of the Buyer under this Agreement may be assigned to any of the
Affiliates of the Buyer and to any third party that purchases the stock or
assets of the Buyer. Each party hereto represents and warrants that this
Agreement has been duly and validly authorized, executed and delivered by such
party and constitutes a valid and binding obligation of such party,
enforceable against such party in accordance with its terms. This Agreement
may be amended only by a writing signed by the parties hereto.
11. GOVERNING LAW. This Agreement shall be subject to and governed by the
laws of the CommonwealthState of
Massachusetts. The parties hereto agree that
venue and jurisdiction with respect to any matter arising under this
Agreement shall be exclusively in the state or federal courts, as applicable,
located in the CommonwealthState of
Massachusetts. Each party submits to the
jurisdiction of such courts in the CommonwealthState of
Massachusetts with
respect to any claims or controversies arising under this Agreement.
12. NO STRICT CONSTRUCTION. The parties hereto have participated jointly
in the negotiation and drafting of this Agreement. In the event an ambiguity
or question of intent or
Exh. C-4
interpretation arises, this Agreement shall be construed as if drafted jointly
by the parties hereto, and no presumption or burden of proof shall arise
favoring or disfavoring any party by virtue of the authorship of any of the
provisions of this Agreement.
13. NOTICE. All notices, requests, demands, claims, and other
communications hereunder will be in writing. Notices, requests, demands,
claims and other communications to the parties hereto shall, unless another
address is set forth in writing, be sent to the address or telecopy number set
forth below:
If to Buyer:
Synta Pharmaceuticals Corp.
00 Xxxxxxxx Xxxxxx
Xxxxxxxxx, XX 00000
Attention:
Facsimile Transmisssion Number:
with a copy to:
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Xxx Xxxxxxxxx Xxxxxx
Xxxxxx, XX 00000
Attention: Xxxxxxx Xxxxxx, Esq.
Facsimile Transmission Number: (000) 000-0000
If to Seller:
Peregrine Financial Corporation
00 Xxxxx Xxxxxx
Xxxxxx, XX 00000
Attention: Xxxx Xxxxxxxxx
Facsimile Transmission Number: (000) 000-0000
with a copy to:
Xxxxx, Xxxxxxx & Xxxxxxxxx, LLP
000 Xxxx Xxxxxx
Xxxxxx, XX 00000
Attention: Xxxxx Xxxx, Esq.
Facsimile Transmission Number: (000) 000-0000
If to the Stockholder:
CMAC, LLC
00 Xxxxx Xxxxxx
Xxxxxx, XX 00000
Attention: Xxxx Xxxxxxxxx
Facsimile Transmission Number: (000) 000-0000
Exh. C-5
with a copy to:
Xxxxx, Xxxxxxx & Xxxxxxxxx, LLP
000 Xxxx Xxxxxx
Xxxxxx, XX 00000
Attention: Xxxxx Xxxx, Esq.
Facsimile Transmission Number: (000) 000-0000
Any party may send any notice, request, demand, claim, or other communication
hereundcr to the intended recipient at the address set forth above using any
other means (including personal delivery, expedited courier, messenger service,
telecopy, telex, ordinary mail, or electronic mail), but no such notice,
request, demand, claim, or other communication shall be deemed to have been duly
given unless and until it actually is received by the intended recipient. Any
party may change the address to which notices, requests, demands, claims, and
other communications hereunder are to be delivered by giving the other Parties
notice in the manner herein set forth.
14. Notwithstanding any of the foregoing, as used in this Agreement in
connection with the term "Stockholder", the term "Affiliates" shall not include
any member of the Stockholder or any principals of any members of the
Stockholder.
[Signature Page Follows]
IN WITNESS WHEREOF, each of the parties has caused this Non-Competition,
Non-Solicitation and Confidentiality Agreement to be duly executed, all as of
the day and year first above written.
BUYER:
SYNTA PHARMACEUTICALS CORP.
By:
-----------------------
Name:
Title:
SELLER:
[NAME OF ENTITY]
By:
-----------------------
Name:
Title:
Exh. C-6
STOCKHOLDER:
CMAC, LLC
By:
-----------------------
Name:
Title:
Exh. C-7
EXHIBIT D
FORM OF PATENT ASSIGNMENT
This PATENT ASSIGNMENT is made as of______________, 200__ by
______________________, an individual with his principal residence at
__________________________________________("ASSIGNOR").
RECITALS
WHEREAS, Assignor is the beneficial owner of all rights, title and
interests in a certain United States Patent as identified on SCHEDULE I attached
hereto (the "PATENT");
WHEREAS, pursuant to the Transaction Agreement dated as of______________,
_____________________ (the "TRANSACTION AGREEMENT") by and among
Assignor,________________________, a _______________________("ASSIGNEE") and the
Investor named therein, Assignor has agreed to transfer certain of its assets
and the intellectual property rights thereto, including, without limitation, the
Patent, to Assignee; and
WHEREAS, Assignee desires to acquire all rights, title and interests in, to
and under said Patent.
NOW, THEREFORE, for good and valuable consideration set forth in the
Transaction Agreement, the receipt and sufficiency of which is hereby
acknowledged by Assignor,
1. Assignor hereby conveys, assigns, transfers and delivers absolutely to
Assignee, its successors and assigns free from encumbrances, (i) all rights,
title and interests throughout the world in, to and under the Patent, and the
underlying inventions described therein and any United States or foreign
reissues, divisions, renewals, extensions, provisionals, continuations and
continuations-in-part thereof, and substitutes therefor, and all letters patent
of the United States which have been or may be granted thereon and all foreign
counterparts thereof, together with all rights and powers arising or accrued
therefrom including, without limitation, the right to xxx and recover damages
and other remedies for future or past infringements of the Patent and to fully
and entirely stand in the place of Assignor in all matters related thereto and
(ii) the right to apply for, prosecute and obtain patent or similar protection
throughout the world in respect of the inventions claimed in the Patents
including the right to claim priority therefrom to the intent that the grant of
any patents or similar protection shall be in the name of and vest in the
Assignee. Assignor agrees to take such further action and to execute such
additional documents as may be necessary to perfect Assignee's title in and to
the Patent and all foreign counterparts thereof. In addition, Assignor hereby
conveys, assigns, transfers and delivers to Assignee, its successors and
assigns, all of its right, title and interest throughout the world in and to all
lab notes, prototypes, product definition, market analysis, marketing studies,
draft patent applications, any and all correspondence with the United States
Patent and Trademark Office or any foreign patent office, trade secrets,
nondisclosure agreements, invention agreements, noncompete agreements and any
other document recording the secret knowledge of Assignor relating to the
Patent.
Exh. D-1
2. Assignor hereby requests the Commissioner of Patents and Trademarks
(the "COMMISSIONER") to record this Patent Assignment to Assignee. Assignor
hereby further requests the Commissioner to issue any and all letters patent of
the United States or derived from the Patent to Assignee as assignee of the
entire interest. Assignor hereby covenants that the Commissioner has full right
to convey the entire interest herein assigned, and that Assignor has not
executed, and will not execute, any agreements inconsistent herewith.
3. GENERAL PROVISIONS. This Agreement will be governed by, and construed
and enforced in accordance with, the substantive laws of the State of Delaware,
without regard to its principles of conflicts of laws. This Agreement may not be
supplemented, altered or modified in any manner except by a writing signed by
both parties hereto. The failure of either party to enforce any terms or
provisions of this Assignment will not waive any rights under such terms and
provisions. This Agreement may be executed by facsimile signature and in
counterparts, each of which will be an original and all of which when taken
together will constitute one and the same Instrument.
IN WITNESS WHEREOF, the undersigned has caused this Patent Assignment to be
executed as of the day and year first written above.
ASSIGNOR
----------------------------
THE COMMONWEALTH OF
MASSACHUSETTS
County of )
On this the____________day of_______________, 200__before me personally
appeared ________________to me personally known, and known to me to be the
person who signed the foregoing assignment, and acknowledged the signing of same
as his free act and deed.
---------------------------------
Notary Public
My commission expires____________
Acknowledged and accepted:
ASSIGNEE
BY:
------------------------------
Name:
Title:
Exh. D-2
SCHEDULE I
TO
PATENT ASSIGNMENT
U.S. PATENT NO. TITLE ISSUE DATE
Exh. D-3
EXHIBIT E
FORM OF LICENSE AGREEMENT
This Agreement (together with Exhibit A attached hereto, this "Agreement")
is made and entered into as of the_________day of_____________, 2003
(the "Effective Date"), by and between SYNTA PHARMACEUTICALS, INC. ("LICENSOR"),
organized and existing under the laws of the state of Delaware, having its
principal office at 00 Xxxxxxxx Xxxxxx, Xxxxxxxxx, Xxxxxxxxxxxxx 00000, and KAVA
PHARMACEUTICALS, INC. ("LICENSEE"), a corporation organized and existing under
the laws of the state of Delaware, having its principal office at 00 Xxxxx
Xxxxxx, Xxxxx 000, Xxxxxx, Xxxxxxxxxxxxx 00000.
WHEREAS, LICENSOR, as of the closing of an asset sale between the parties
concurrently herewith, is the owner of certain PATENT RIGHTS, and the LICENSOR
has the right to grant licenses under such PATENT RIGHTS; and
WHEREAS, LICENSEE desires to obtain certain licenses under the PATENT
RIGHTS upon the terms and conditions hereinafter set forth.
NOW, THEREFORE, in consideration of the premises and the mutual covenants
contained herein, the parties hereto, intending to be legally bound, agree as
follows:
ARTICLE 1 - DEFINITIONS
For purposes of this Agreement, the following words and phrases shall
have the following meanings:
1.1 AFFILIATE shall mean any business entity which directly or indirectly
is the legal or beneficial owner of, or controls greater than fifty-percent
(50%) of the issued and voting capital stock or other share participation of a
party hereto.
1.2 CONFIDENTIAL INFORMATION shall mean information, including but not
limited to, regarding existing or proposed research, development efforts,
business or products; marketing and distribution data, methods, plans and
efforts; the identities of and the course of dealing with actual and prospective
customers, contractors and suppliers; and any other materials that have not been
made available to the general public. Information in written form shall be
Exh. E-1
marked "Confidential" in order to qualify for such treatment. Information in
other than written form shall be confirmed in writing within thirty (30) days of
disclosure in order to qualify for such treatment.
1.3 FIELD shall mean the development, manufacture and sale of kava kava
extracts, and components thereof, for use in beverages and drink formulations.
1.4 LICENSED PRODUCT shall mean any product or part thereof which is:
(a) covered in whole or in part by an issued, unexpired or pending
claim contained in the PATENT RIGHTS in the country in which any such product or
part thereof is made, used or sold; or
(b) manufactured by using, or is employed to practice, a process
which is covered in whole or in part by an issued, unexpired claim or a pending
claim contained in the PATENT RIGHTS in the country in which such process is
used or in which such product or part thereof is used or sold.
1.5 PATENT RIGHTS shall mean LICENSOR intellectual property described
below:
(a) The United States and foreign patents (including, reissues,
reexaminations, conversions, patents of addition, and extensions thereof)
and/or patent applications listed in EXHIBIT A;
(b) United States and foreign patents (including, reissues,
reexaminations, conversions, patents of addition, and extensions thereof)
issued from the applications listed in Exhibit A and from divisionals,
continuations, and continuations-in-part of these applications;
(c) Claims of U.S. and foreign continuation-in-part
applications, and of the resulting patents, which are directed to subject
matter specifically described in the U.S. and foreign applications listed
in Exhibit A;
(d) Claims of all foreign patent applications, and of the
resulting patents, which are directed to subject matter specifically
described in the United States patents and/or patent applications described
in (a), (b) or (c) above.
1.6 SUBLICENSEE shall mean any third party to whom LICENSEE grants a
sublicense of some or all of the rights granted to LICENSEE pursuant to Article
2 hereof.
Exh. E-2
1.7 TERM shall have the meaning set forth in Section 7.1, hereof.
1.8 TERRITORY shall mean worldwide.
ARTICLE 2 - GRANT
2.1 LICENSE GRANT. LICENSOR for the sum of ten (US$ 10.00) U.S. dollars
and other good and valuable consideration the receipt of which is hereby
acknowledged, hereby grants to LICENSEE, subject to the terms and conditions of
this Agreement, a fully paid-up and royalty- free right and exclusive license,
including the right to grant sublicenses in accordance with Section 2.2 below,
under the PATENT RIGHTS to make, have made, use and sell LICENSED PRODUCTS in
the FIELD during the TERM in the TERRITORY.
2.2 RIGHT TO SUBLICENSE. LICENSEE shall have the right to grant to any
SUBLICENSEE sublicenses to all or any portion of its rights under the license
granted pursuant to this Article 2; PROVIDED, HOWEVER, that (a) LICENSOR shall
be notified in writing of any and all potential sublicenses, and (b) any and all
sublicenses shall be consistent with the terms and conditions of this Agreement.
2.3 RETAINED RIGHTS. LICENSOR hereby retains the right to practice the
PATENT RIGHTS for any and all uses outside of the FIELD.
ARTICLE 3 - CONFIDENTIALITY
3.1 Each party will maintain the confidential nature of CONFIDENTIAL
INFORMATION it receives from the other and shall, at a minimum, take those
precautions that it utilizes to protect its own confidential information, but
not less than a commercially reasonable standard of care, and shall refrain from
using any of the CONFIDENTIAL INFORMATION except in connection with this
Agreement. The foregoing provisions shall not apply to any information that is:
(i) generally available to the public immediately prior to the time of
disclosure; (it) becomes available to the public in compliance with provisions
of this Agreement; (iii) is independently developed by the receiving party as
demonstrated by written evidence, (iv) is received from a third party, provided
that such third party did not receive the information by any unauthorized
disclosure; or (v) is disclosed in compliance with an order of an administrative
or regulatory agency or court of competent jurisdiction. This obligation of
confidentiality will
Exh. E-3
commence on the Effective Date and continue until five (5) years after the
expiration or termination of this Agreement.
3.2 In the event that any party is requested or required (by oral question
or request for information or documents in any legal proceeding, interrogatory,
subpoena, civil investigative demand, or similar process) to disclose any
CONFIDENTIAL INFORMATION, that party will notify the other promptly of the
request or requirement so that the other party or parties may seek an
appropriate protective order. A party may disclose the CONFIDENTIAL INFORMATION
subject to order of an administrative or regulatory agency or court of competent
jurisdiction; provided, however, that such party shall use its best efforts to
obtain, at the request of the other party, a protective order or other assurance
that confidential treatment will be accorded to such portion of the CONFIDENTIAL
INFORMATION required to be disclosed.
3.3 For the purposes of this Article 3, a "party" is specifically deemed
to include any AFFILIATE thereof.
ARTICLE 4 - INTELLECTUAL PROPERTY
4.1 PATENT FILING, PROSECUTION AND MAINTENANCE. Subject to the other
terms of this Article 4, LICENSOR shall be solely responsible for preparing,
filing, prosecuting, obtaining and maintaining, at its sole cost, expense and
discretion, all PATENT RIGHTS in all countries. LICENSOR will keep LICENSEE
reasonably informed of the status of all actions it takes with respect to the
PATENT RIGHTS that are licensed to LICENSEE hereunder. LICENSOR shall also
provide written notice to LICENSEE prior to taking or failing to take any such
action that would reasonably be expected to affect the scope or validity of the
PATENT RIGHTS licensed to LICENSEE hereunder, such that LICENSEE has a
reasonable opportunity to review and provide comment. If LICENSOR determines in
its sole discretion not to undertake the filing of any patent application or
submission with respect to any of the PATENT RIGHTS licensed to LICENSEE
hereunder, then it shall give LICENSEE prompt written notice of same, at which
time LICENSEE may undertake such filing at its own expense, in LICENSOR's name.
ARTICLE 5 - INFRINGEMENT ACTIONS
Exh. E-4
5.1 NOTICE OF INFRINGEMENT. If, during the TERM, either party learns of
any actual, alleged or threatened infringement by a third party of any PATENT
RIGHTS, such party shall promptly notify the other party and shall provide such
other party with all available evidence of such infringement.
5.2 RIGHTS OF PARTIES. LICENSOR shall have the first right (but not the
obligation), at its own expense and with legal counsel of its own choice, to
bring suit (or take other appropriate legal action) against any actual, alleged
or threatened infringement of the PATENT RIGHTS. LICENSEE shall have the right,
at its own expense, to be represented in any such action by LICENSOR by counsel
of LICENSEE's own choice; PROVIDED, HOWEVER, that under no circumstances shall
the foregoing affect the right of LICENSOR to control the suit as described in
the first sentence of this Section 5.2. If LICENSOR does not file any action or
proceeding against any material infringement of the PATENT RIGHTS within the
FIELD within six (6) months after the later of (i) LICENSOR's notice to LICENSEE
under Section 5.1 above. (ii) LICENSEE's notice to LICENSOR under Section 5.1
above, or (iii) a written request from LICENSEE to take action with respect to
such infringement, then LICENSEE shall have the right (but not the obligation),
at its own expense, to bring suit (or take other appropriate legal action)
against such actual, alleged or threatened infringement, with legal counsel of
its own choice, but shall not be permitted to settle any such suit without the
prior consent of LICENSOR, which consent shall not be unreasonably withheld. Any
damages, monetary awards or other amounts recovered, whether by judgment or
settlement, pursuant to any suit, proceeding or other legal action taken under
this Section 5.2, shall applied as follows:
(a) first, to reimburse the parties for their respective costs and
expenses (including reasonable attorneys' fees and costs) incurred in
prosecuting such enforcement action;
(b) second, to LICENSEE in reimbursement for any lost sales
associated with LICENSED PRODUCTS directly attributable to such
infringement; and
(c) third, any amounts remaining shall be allocated as follows: (a)
if LICENSOR is the party bringing such suit or proceeding or taking such
other legal action, one hundred percent (100%) to LICENSOR, (b) if LICENSEE
is the party bringing such suit or
Exh. E-5
proceeding or taking such other legal action, one hundred percent (100%) to
LICENSEE, and (c) if the suit is brought jointly by the parties, fifty percent
(50%) to each party.
If a party brings any such action or proceeding hereunder, the other party
agrees to be joined as party plaintiff if necessary to prosecute such action or
proceeding, and to give the party bringing such action or proceeding reasonable
assistance and authority to file and prosecute the suit; PROVIDED, HOWEVER, that
neither party shall be required to transfer any right, title or interest in or
to any property to the other party or any third party to confer standing on a
party hereunder.
ARTICLE 6 - INDEMNIFICATION / LIMITATION OF LIABILITY
6.1 LICENSEE shall at all times during the term of this Agreement and
thereafter indemnify, defend and hold LICENSOR, its trustees, officers,
employees and affiliates harmless against all claims and expenses, including
legal expenses and reasonable attorneys' fees, arising out of the death of or
injury to any person or persons or out of any damage to property or the
environment, and against any other claim, proceeding, demand, expense and
liability of any kind whatsoever resulting from the clinical investigation,
production, manufacture, sale, use, lease, consumption or advertisement of any
LICENSED PRODUCT by LICENSEE or any AFFILIATE of LICENSEE or any SUBLICENSEE,
unless directly caused by the gross negligence or willful misconduct of
LICENSOR.
6.2 EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, LICENSOR
MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS
OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS
FOR A PARTICULAR PURPOSE, AND VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR
PENDING. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION OR
WARRANTY GIVEN BY LICENSOR THAT THE PRACTICE BY LICENSEE OF THE LICENSE
GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY.
Exh. E-6
ARTICLE 7 - TERMINATION
7.1 TERM. Unless earlier terminated as provided herein, the term of this
Agreement shall commence on the Effective Date and shall continue until the last
to expire patent or patent claim under the PATENT RIGHTS (the "TERM").
7.2 LICENSOR shall have the right to terminate this Agreement if LICENSEE
shall default in the performance of any of the obligations herein contained and
such default has not been cured within ninety (90) days after receiving written
notice thereof from LICENSOR.
7.3 In the event this Agreement is terminated for any reason, then upon
the request by a disclosing party, the receiving party will promptly return or
certify the destruction of all CONFIDENTIAL INFORMATION it received from the
disclosing party along with all copies made by the receiving party. Upon such a
request, the disclosing party's CONFIDENTIAL INFORMATION contained on data
storage media shall be certified as being deleted there from.
7.4 Upon termination of this Agreement, neither party shall be released
from any obligation that matured prior to the effective date of such
termination; provided, LICENSEE and any SUBLICENSEE may, for a period of six (6)
months or such longer time period (if any) on which the parties mutually agree
in writing, sell all LICENSED PRODUCTS which LICENSEE (or any SUBLICENSEE)
produced prior to the effective date of such termination. Without limitation of
the foregoing, the provisions of Articles 3, and 6 shall survive termination of
this Agreement.
ARTICLE 8 - NOTICES
8.1 Any notice or communication pursuant to this Agreement shall be
sufficiently made or given if sent by certified or registered mail, postage
prepaid, or by overnight courier, with proof of delivery by receipt, addressed
to the address below or as either party shall designate by written notice to the
other party.
In the case of LICENSOR:
SYNTA PHARMACEUTICALS, INC.
00 Xxxxxxxx Xxxxxx
Xxxxxxxxx, Xxxxxxxxxxxxx 00000
Attention: President
Exh. E-7
In the case of LICENSEE:
Peregrine Financial Corporation
Attn: Xx. Xxxx Xxxxxxxxx
00 Xxxxx Xxxxxx, Xxxxx 000
Xxxxxx, Xxxxxxxxxxxxx 00000
ARTICLE 9 - MISCELLANEOUS
9.1 This Agreement is not assignable without the prior written consent of
LICENSOR and any attempt to do so shall be null and void; however, LICENSEE may,
upon prior written notice to LICENSOR, assign this Agreement and all its rights
and obligations hereunder to a third party, including Drinks That Work, Inc.,
solely in connection with the LICENSEE'S winding-down and liquidation of its
business. This Agreement may be assigned by LICENSOR provided that any successor
in interest assumes all rights and obligations of LICENSOR hereunder.
9.2 This Agreement may not be amended or modified except by the execution
of a written instrument signed by the parties hereto.
9.3 Nothing in this Agreement shall be construed to deem either party as
agent for the other.
9.4 This Agreement shall be governed, interpreted and construed in
accordance with the laws of the Commonwealth of
Massachusetts, irrespective of
choice of laws provisions. Both parties shall use reasonable efforts to resolve
by mutual agreement any disputes, controversies, claims or difference which may
arise from, under, out of or in connection with this Agreement. If such
disputes, controversies, claims or differences cannot be settled between the
parties, any dispute resolution proceeding shall take place in the United
States, but if either party files a claim in a state or federal court, such
claim shall be filed in the state or federal courts in the Commonwealth of
Massachusetts. Nothing herein shall alter or affect any other rights either
party may have to redress any breach or act of the other party.
9.5 Nothing contained in this Agreement shall be construed as conferring
upon either party any right to use in advertising, publicity or other
promotional activities any name, trade name, trademark, or other designation of
the other party, including any contraction, abbreviation, or simulation of any
of the foregoing. Without the express written approval of the other party,
Exh. E-8
neither party shall use any designation of the other party in any promotional
activity associated with this Agreement, including without limitation, any
LICENSED PRODUCT. Neither party shall issue any press release or make any public
statement in regard to this Agreement without the prior written approval of the
other party.
9.6 If one or more of the provisions of this Agreement shall be held
invalid, illegal or unenforceable, the remaining provisions shall not in any way
be affected or impaired thereby. In the event any provision is held illegal or
unenforceable, the parties shall use reasonable efforts to substitute a valid,
legal and enforceable provision which, insofar as is practical, implements
purposes of the provision held invalid, illegal or unenforceable.
9.7 Failure at any time to require performance of any of the provisions
herein shall not waive or diminish a party's right thereafter to demand
compliance therewith or with any other provision. Waiver of any default shall
not waive any other default. A party shall not be deemed to have waived any
rights hereunder unless such waiver is in writing and signed by a duly
authorized officer of the party making such waiver.
9.8 The parties acknowledge that this Agreement sets forth the entire
understanding and intentions of the parties hereto as to the subject matter
hereof and supersedes all previous understandings between the parties, written
or oral, regarding such subject matter.
[The remainder of this page left intentionally blank.]
Exh. E-9
IN WITNESS WHEREOF, the parties have set their hands and seals as of the
date set forth on the first page hereof.
For LICENSOR For LICENSEE
SYNTA PHARMACEUTICALS, INC. KAVA PHARMACEUTICALS, INC.
------------------------ -----------------------
Name: Name:
Title: Title:
Exh. E-10
EXHIBIT A
COUNTRY SERIAL NUMBERS FILING DETAILS
---------------------- -------------------------------- -------------------------
United States Patent Appln. No. 09/584,220 Filed May 31, 0000
Xxxxxx Xxxxxx Patent Appln. No. 09/962,514 Filed September 24, 0000
Xxxxxx Xxxxxx Patent Appln. No. 10/396,117 Filed March 25, 2003
International PCT Patent Appln. No. Filed June 1, 2000
Taiwan Patent Appln. No. 89112231 Filed June 21, 0000
Xxxxxx Xxxxxx Patent Appln. No. 09/853,304 Filed May 11, 0000
Xxxxxx Xxxxxx Patent Appln. No. 10/010,201 Filed November 30, 0000
Xxxxxx Xxxxxx Patent Appln. No. 60/311,437 Filed August 10, 0000
Xxxxxx Xxxxxx Patent Appln. No. 10/214,624 Filed August 8, 2002
PCT Patent Appln. No. Filed Xxxxxx 0, 0000
Xxxxxx Patent Appln. No. 91117959 Filed August 9, 0000
Xxxxxx Xxxxxx Patent Appln. No. 09/923,462 Filed August 6, 2001
PCT Patent Appln. No. Filed Xxxxxx 0, 0000
Xxxxxx Patent Appln. No. 91117646 Filed August 6, 0000
Xxxxxx Xxxxxx Patent Appln. No. 60/328,986 Filed October 12, 0000
Xxxxxx Xxxxxx Patent Appln. No. 10/269,722 Filed October 11, 2002
PCT Patent Appln. No. Filed October 15, 0000
Xxxxxx Xxxxxx Patent Appln. No. 60/351,167 Filed January 22, 0000
Xxxxxx Xxxxxx Patent Appln. No. 10/349,194 Filed January 22, 2003
PCT Patent Appln No. Filed May 13, 2002
Taiwan Patent Appln No. 91109804 Filed May 10, 0000
Xxxxxx Xxxxxx Patent Appln. No. 60/359,864 Filed February 27, 0000
Xxxxxx Xxxxxx Patent Appln. No. 10/376,800 Filed February 27, 2003
PCT Patent Appln. No. Filed February 27, 2003
TRA 1862567v2
Exh. E-11
